Boston Scientific (BSX) 10-Q 8 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 30, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'BOSTON SCIENTIFIC CORPORATION	'
Entity Central Index Key	'0000885725	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	1,322,675,633

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Net sales	$1,774	$1,761
Cost of products sold	537	578
Gross profit	1,237	1,183
Operating expenses:	'	'
Selling, general and administrative expenses	666	631
Research and development expenses	191	204
Royalty expense	40	41
Amortization expense	109	103
Goodwill impairment charges	0	423
Intangible asset impairment charges	55	0
Contingent consideration (benefit) expense	-22	-23
Restructuring charges	20	10
Litigation-related (credits) charges	-7	130
Gain on divestiture	-12	-6
Operating expenses	1,040	1,513
Operating income (loss)	197	-330
Other (expense) income:	'	'
Interest expense	-54	-65
Other, net	3	1
Income (loss) before income taxes	146	-394
Income tax expense (benefit)	13	-40
Net income (loss)	$133	($354)
Net income (loss) per common share — basic	$0.10	($0.26)
Net income (loss) per common share — assuming dilution	$0.10	($0.26)
Weighted-average shares outstanding	'	'
Basic	1,321.70	1,351.90
Assuming dilution	1,349.20	1,351.90

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Net income (loss)	$133	($354)
Foreign currency translation adjustment	-6	3
Net change in unrealized gains and losses on derivative financial instruments, net of tax	-27	75
Net change in certain retirement plans	-1	0
Total other comprehensive income (loss)	-34	78
Total comprehensive income (loss)	$99	($276)

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$191	$217
Trade accounts receivable, net	1,217	1,307
Inventories	926	897
Deferred income taxes	279	288
Prepaid expenses and other current assets	323	302
Total current assets	2,936	3,011
Property, plant and equipment, net	1,539	1,546
Goodwill	5,697	5,693
Other intangible assets, net	5,802	5,950
Other long-term assets	361	371
TOTAL ASSETS	16,335	16,571
Current liabilities:	'	'
Current debt obligations	4	3
Accounts payable	241	246
Accrued expenses	1,275	1,348
Other current liabilities	199	227
Total current liabilities	1,719	1,824
Long-term debt	4,245	4,237
Deferred income taxes	1,439	1,402
Other long-term liabilities	2,398	2,569
Commitments and contingencies	'	'
Stockholders’ equity	'	'
Preferred stock, $.01 par value - authorized 50,000,000 shares, none issued and outstanding	'	'
Common stock, $.01 par value - authorized 2,000,000,000 shares and issued 1,570,033,861 shares as of March 31, 2014 and 1,560,302,634 shares as of December 31, 2013	16	16
Treasury stock, at cost - 247,566,270 shares as of March 31, 2014 and 238,006,570 shares as of December 31, 2013	-1,717	-1,592
Additional paid-in capital	16,599	16,579
Accumulated deficit	-8,436	-8,570
Accumulated other comprehensive income (loss), net of tax	72	106
Total stockholders’ equity	6,534	6,539
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$16,335	$16,571

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Stockholders' Equity:	'	'
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	1,570,033,861	1,560,302,634
Common stock, shares outstanding	1,322,467,591	1,322,296,064
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Treasury shares	247,566,270	238,006,570

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash provided by operating activities	$198	$187
Investing activities:	'	'
Purchases of property, plant and equipment	-59	-53
Proceeds from sale of property, plant and equipment	0	53
Purchases of privately held securities	-6	-4
Proceeds from sales of publicly traded and privately held equity securities and collections of notes receivable	7	0
Payments for acquisitions of businesses, net of cash acquired	-8	0
Payments for investments in companies and acquisitions of certain technologies	-11	-7
Proceeds from business divestitures, net of costs	12	0
Cash used for investing activities	-65	-11
Financing activities:	'	'
Payment of contingent consideration	-12	0
Proceeds from borrowings on credit facilities	285	240
Payments on borrowings from credit facilities	-285	-240
Payments for acquisitions of treasury stock	-125	-100
Cash used to net share settle employee equity awards	-47	-24
Proceeds from issuances of shares of common stock	24	10
Cash used for financing activities	-160	-114
Effect of foreign exchange rates on cash	1	-1
Net increase (decrease) in cash and cash equivalents	-26	61
Cash and cash equivalents at beginning of period	217	207
Cash and cash equivalents at end of period	191	268
Non-cash operating activities:	'	'
Stock-based compensation expense	26	24
Fair value of contingent consideration recorded	$3	$0

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Basis of Presentation [Abstract]	'
BASIS OF PRESENTATION	'
	BASIS OF PRESENTATION
	The accompanying unaudited condensed consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. For further information, refer to the consolidated financial statements and footnotes thereto included in Item 8 of our 2013 Annual Report filed on Form 10-K.
	Additionally, certain prior year cash outflows from net share settling employee equity awards to satisfy their tax withholding requirement have been reclassified from an operating activity to a financing activity within our condensed consolidated statements of cash flows. Amounts reclassified from operating to financing activities on the cash flows were not material.
	Subsequent Events
	We evaluate events occurring after the date of our most recent accompanying unaudited condensed consolidated balance sheets for potential recognition or disclosure in our financial statements. We did not identify any material subsequent events requiring adjustment to our accompanying unaudited condensed consolidated financial statements (recognized subsequent events) for the three month period ended March 31, 2014. Those items requiring disclosure (unrecognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note B - Acquisitions and Note J - Commitments and Contingencies for more information.

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
ACQUISITIONS	'
	ACQUISITIONS
	We did not close any material acquisitions during the first quarters of 2014 and 2013.
	On May 7, 2014, we completed the acquisition of the remaining fully diluted equity of IoGyn, Inc. (IoGyn). Prior to the acquisition, we held approximately 28 percent minority interest in IoGyn in addition to notes receivable of approximately $8 million. Total consideration was comprised of a net cash payment of $65 million at closing to acquire the remaining 72 percent of IoGyn equity and repay outstanding debt. IoGyn has developed the SymphionTM System, a next generation system for hysteroscopic intrauterine tissue removal including fibroids (myomas) and polyps. In March 2014, IoGyn received U.S. FDA approval for the system, and we expect to launch the system in the United States in the second half of 2014. We will integrate the operations of the IoGyn business into our Urology and Women’s Health division.
	Contingent Consideration
	Certain of our acquisitions involve contingent consideration arrangements. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals. In accordance with U.S. GAAP, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We remeasure this liability each reporting period and record changes in the fair value through a separate line item within our consolidated statements of operations.
	Changes in the fair value of our contingent consideration liability were as follows (in millions):
	Balance as of December 31, 2013	$	(501	)
	Amounts recorded related to new acquisitions	(3		)
	Other amounts recorded related to prior acquisitions	(2		)
	Net fair value adjustments	22
	Payments made	12
	Balance as of March 31, 2014	$	(472	)
	As of March 31, 2014, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay was approximately $2.2 billion.
	Contingent consideration liabilities are remeasured to fair value each reporting period using projected revenues, discount rates, probabilities of payment and projected payment dates. The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:
	Contingent Consideration Liability	Fair Value as of March 31, 2014	Valuation Technique	Unobservable Input	Range
	R&D, Regulatory and Commercialization-based Milestones	$87 million	Probability Weighted Discounted Cash Flow	Discount Rate	0.7%-1.4%
				Probability of Payment	85% - 95%
				Projected Year of Payment	2014 - 2015
	Revenue-based Payments	$131 million	Discounted Cash Flow	Discount Rate	11.5% - 15%
				Probability of Payment	0% - 100%
				Projected Year of Payment	2014 - 2018
		$254 million	Monte Carlo	Revenue Volatility	13% - 19%
				Risk Free Rate	LIBOR Term Structure
				Projected Year of Payment	2014-2018
	Increases or decreases in the fair value of our contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing and amount of revenue estimates or in the timing or likelihood of achieving regulatory-, revenue- or commercialization-based milestones. Projected contingent payment amounts related to research and development, regulatory- and commercialization-based milestones and certain revenue-based milestones are discounted back to the current period using a discounted cash flow (DCF) model. Other revenue-based payments are valued using a Monte Carlo valuation model, which simulates future revenues during the earn-out period using management's best estimates. Projected revenues are based on our most recent internal operational budgets and long-range strategic plans. Increases in projected revenues and probabilities of payment may result in higher fair value measurements. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs in isolation may result in a significantly lower or higher fair value measurement.

Divestitures

Divestitures	3 Months Ended
	Mar. 31, 2014
Divestitures and Assets Held for Sale [Abstract]	'
DIVESTITURES	'
	DIVESTITURES
	In January 2011, we closed the sale of our Neurovascular business to Stryker Corporation for a purchase price of $1.500 billion in cash. We received $1.450 billion during 2011, including an upfront payment of $1.426 billion, and $24 million which was placed into escrow and released throughout 2011 upon the completion of local closings in certain foreign jurisdictions. We received $10 million during 2012, $28 million during the second quarter of 2013 and we received the final $12 million of consideration in January 2014. Due to our continuing involvement in the operations of the Neurovascular business following the divestiture, the divestiture did not meet the criteria for presentation as a discontinued operation.
	Revenue generated by the Neurovascular business was $2 million in the first quarter of 2014 and $36 million in the first quarter of 2013. Our sales related to our divested Neurovascular business have declined as the various transition services and supply agreements have terminated.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
GOODWILL AND OTHER INTANGIBLE ASSETS	'
	GOODWILL AND OTHER INTANGIBLE ASSETS
	The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill as of March 31, 2014 and December 31, 2013 are as follows:
			As of
			March 31, 2014								December 31, 2013
			Gross Carrying				Accumulated				Gross Carrying				Accumulated
							Amortization/								Amortization/
	(in millions)		Amount				Write-offs				Amount				Write-offs
	Amortizable intangible assets
	Technology-related		$	8,232			$	(3,431	)		$	8,272			$	(3,342	)
	Patents		521				(332		)		513				(326		)
	Other intangible assets		846				(493		)		845				(479		)
			$	9,599			$	(4,256	)		$	9,630			$	(4,147	)
	Unamortizable intangible assets
	Goodwill		$	15,597			$	(9,900	)		$	15,593			$	(9,900	)
	Technology-related		197				—				197				—
			$	15,794			$	(9,900	)		$	15,790			$	(9,900	)
	In addition, we had $262 million and $270 million of in-process research and development intangible assets as of March 31, 2014 and December 31, 2013, respectively.
	The following represents our goodwill balance by global reportable segment:
	(in millions)		Cardiovascular				Rhythm Management				MedSurg				Total
	Balance as of December 31, 2013		$	3,252			$	294			$	2,147			$	5,693
	Purchase price adjustments		—				(2		)		—				(2		)
	Goodwill acquired		—				—				6				6
	Goodwill written off		—				—				—				—
	Other changes in carrying amount *		7				—				(7		)		—
	Balance as of March 31, 2014		$	3,259			$	292			$	2,146			$	5,697
	* In the first quarter of 2014, we reallocated $7 million of goodwill between Cardiovascular and MedSurg as a result of the realignment of certain product lines from Endoscopy to Peripheral Interventions as of January 1, 2014.
	Goodwill Impairment Testing and Charge
	We test our goodwill balances during the second quarter of each year for impairment, or more frequently if indicators are present or changes in circumstances suggest that an impairment may exist. Refer to Note D - Goodwill and Other Intangible Assets contained in Item 8 of our 2013 Annual Report filed on Form 10-K for discussion of our most recent goodwill impairment test performed in the second quarter of 2013.
	2013 Charge
	Following our reorganization from regions to global business units and our reallocation of goodwill on a relative fair value basis as of January 1, 2013, we conducted the first step of the goodwill impairment test for all global reporting units. As of January 1, 2013, the fair value of each global reporting unit exceeded its carrying value, with the exception of the global Cardiac Rhythm Management (CRM) reporting unit. In accordance with ASC Topic 350, Intangibles—Goodwill and Other (Topic 350) and our accounting policies, we tested the global CRM intangible assets and goodwill for impairment and recorded a non-cash goodwill impairment charge of $423 million ($422 million after-tax) to write down the goodwill to its implied fair value as of January 1, 2013 as a result of this analysis. The primary driver of this impairment charge was our reorganization from geographic regions to global business units as of January 1, 2013, which changed the composition of our reporting units. As a result of the reorganization, any goodwill allocated to the global CRM reporting unit was no longer supported by the cash flows of other businesses. Under our former reporting unit structure, the goodwill allocated to our regional reporting units was supported by the cash flows from all businesses in each international region. The hypothetical tax structure of the global CRM business and the global CRM business discount rate applied were also contributing factors to the goodwill impairment charge. Refer to Note D - Goodwill and Other Intangible Assets contained in Item 8 of our 2013 Annual Report filed on Form 10-K for details on the 2013 goodwill impairment charge.
	The following is a rollforward of accumulated goodwill write-offs by global reportable segment:
	(in millions)	Cardiovascular				Rhythm Management				MedSurg				Total
	Accumulated write-offs as of December 31, 2013	$	(1,479	)		$	(6,960	)		$	(1,461	)		$	(9,900	)
	Goodwill written off	—				—				—				—
	Accumulated write-offs as of March 31, 2014	$	(1,479	)		$	(6,960	)		$	(1,461	)		$	(9,900	)
	Intangible Asset Impairment Testing
	On a quarterly basis, we monitor for events or other potential indicators of an impairment that would warrant an interim impairment test of our intangible assets. Refer to Note D - Goodwill and Other Intangible Assets contained in Item 8 of our 2013 Annual Report filed on Form 10-K for a discussion of future events that would have a negative impact on the recoverability of our $4.305 billion of CRM-related amortizable intangible assets. Our CRM-related amortizable intangibles are at higher risk of potential failure of the first step of the amortizable intangible recoverability test in future reporting periods. An impairment of a material portion of our CRM-related amortizable intangibles carrying value would likely occur if the second step of the amortizable intangible test is required in a future reporting period. Refer to Critical Accounting Policies and Estimates within our Management's Discussion and Analysis of Financial Condition and Results of Operations contained in Item 7 of our 2013 Annual Report filed on Form 10-K for a discussion of key assumptions used in our testing.
	During the first quarter of 2014, as a result of lower estimates of the resistant hypertension market following the announcement of data from a competitor's clinical trial, we performed an interim impairment test of our in-process research and development projects and core technology associated with our acquisition of Vessix Vascular, Inc. (Vessix). The impairment assessments were based upon probability-weighted cash flows of potential future scenarios. Based on our impairment assessment, which included an initial undiscounted recoverability cash flow test for core technology, and lower expected future cash flows associated with our Vessix-related intangible assets, we recorded pre-tax impairment charges of $55 million in the first quarter of 2014 to write down the balance of these intangible assets to their fair value. We recorded this amount in the intangible asset impairment charges caption in our accompanying unaudited condensed consolidated statements of operations.
	The nonrecurring Level 3 fair value measurements of our intangible asset impairment analysis included the following significant unobservable inputs:
	Intangible Asset	Valuation Date	Fair Value	Valuation Technique	Unobservable Input	Rate
	In-Process R&D	31-Mar-14	$6 million	Income Approach - Excess Earnings Method	Discount Rate	20%
	Core Technology	31-Mar-14	$64 million	Income Approach - Excess Earnings Method	Discount Rate	15%

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
FAIR VALUE MEASUREMENTS	'
	FAIR VALUE MEASUREMENTS
	Derivative Instruments and Hedging Activities
	We develop, manufacture and sell medical devices globally and our earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates and interest rates. We address these risks through a risk management program that includes the use of derivative financial instruments, and operate the program pursuant to documented corporate risk management policies. We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with ASC Topic 815, Derivatives and Hedging (Topic 815). In accordance with Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship. Our derivative instruments do not subject our earnings or cash flows to material risk, as gains and losses on these derivatives generally offset losses and gains on the item being hedged. We do not enter into derivative transactions for speculative purposes and we do not have any non-derivative instruments that are designated as hedging instruments pursuant to Topic 815.
	Currency Hedging
	We are exposed to currency risk consisting primarily of foreign currency denominated monetary assets and liabilities, forecasted foreign currency denominated intercompany and third-party transactions and net investments in certain subsidiaries. We manage our exposure to changes in foreign currency exchange rates on a consolidated basis to take advantage of offsetting transactions. We use both derivative instruments (currency forward and option contracts), and non-derivative transactions (primarily European manufacturing and distribution operations) to reduce the risk that our earnings and cash flows associated with these foreign currency denominated balances and transactions will be adversely affected by foreign currency exchange rate changes.
	Designated Foreign Currency Hedges
	All of our designated currency hedge contracts outstanding as of March 31, 2014 and December 31, 2013 were cash flow hedges under Topic 815 intended to protect the U.S. dollar value of our forecasted foreign currency denominated transactions. We record the effective portion of any change in the fair value of foreign currency cash flow hedges in other comprehensive income (OCI) until the related third-party transaction occurs. Once the related third-party transaction occurs, we reclassify the effective portion of any related gain or loss on the foreign currency cash flow hedge to earnings. In the event the hedged forecasted transaction does not occur, or it becomes no longer probable that it will occur, we reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. We had currency derivative instruments designated as cash flow hedges outstanding in the contract amount of $2.736 billion as of March 31, 2014 and $2.564 billion as of December 31, 2013.
	We recognized net gains of $21 million in earnings on our cash flow hedges during the first quarter of 2014, as compared to net losses of $6 million during the first quarter of 2013. All currency cash flow hedges outstanding as of March 31, 2014 mature within 36 months. As of March 31, 2014, $112 million of net gains, net of tax, were recorded in accumulated other comprehensive income (AOCI) to recognize the effective portion of the fair value of any currency derivative instruments that are, or previously were, designated as foreign currency cash flow hedges, as compared to net gains of $139 million as of December 31, 2013. As of March 31, 2014, $69 million of net gains, net of tax, may be reclassified to earnings within the next twelve months.
	The success of our hedging program depends, in part, on forecasts of transaction activity in various currencies (primarily Japanese yen, Euro, British pound sterling, Australian dollar and Canadian dollar). We may experience unanticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activity during periods of currency volatility. In addition, changes in foreign currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.
	Non-designated Foreign Currency Contracts
	We use currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These currency forward contracts are not designated as cash flow, fair value or net investment hedges under Topic 815; are marked-to-market with changes in fair value recorded to earnings; and are entered into for periods consistent with currency transaction exposures, generally less than one year. We had currency derivative instruments not designated as hedges under Topic 815 outstanding in the contract amount of $2.157 billion as of March 31, 2014 and $1.952 billion as of December 31, 2013.
	Interest Rate Hedging
	Our interest rate risk relates primarily to U.S. dollar borrowings, partially offset by U.S. dollar cash investments. We have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates by converting floating-rate debt into fixed-rate debt or fixed-rate debt into floating-rate debt.
	We designate these derivative instruments either as fair value or cash flow hedges under Topic 815. We record changes in the value of fair value hedges in interest expense, which is generally offset by changes in the fair value of the hedged debt obligation. Interest payments made or received related to our interest rate derivative instruments are included in interest expense. We record the effective portion of any change in the fair value of derivative instruments designated as cash flow hedges as unrealized gains or losses in OCI, net of tax, until the hedged cash flow occurs, at which point the effective portion of any gain or loss is reclassified to earnings. We record the ineffective portion of our cash flow hedges in interest expense. In the event the hedged cash flow does not occur, or it becomes no longer probable that it will occur, we reclassify the amount of any gain or loss on the related cash flow hedge to interest expense at that time.
	In the fourth quarter of 2013, we entered into interest rate derivative contracts having a notional amount of $450 million to convert fixed-rate debt into floating-rate debt, which we designated as fair value hedges, and had $450 million outstanding as of March 31, 2014. We assessed at inception, and re-assess on an ongoing basis, whether the interest rate derivative contracts are highly effective in offsetting changes in the fair value of the hedged fixed-rate debt. We recognized in interest expense a $10 million loss on our hedged debt and a $10 million gain on the related interest rate derivative contract during the first quarter of 2014.
	In prior years, we terminated certain interest rate derivative contracts, including fixed-to-floating interest rate contracts, designated as fair value hedges, and floating-to-fixed treasury locks, designated as cash flow hedges. We are amortizing the gains and losses on these derivative instruments upon termination into earnings as a reduction of interest expense over the remaining term of the hedged debt, in accordance with Topic 815. The carrying amount of certain of our senior notes included unamortized gains of $52 million as of March 31, 2014 and $54 million as of December 31, 2013, and unamortized losses of $2 million as of March 31, 2014 and $2 million as of December 31, 2013, related to the fixed-to-floating interest rate contracts. In addition, we had pre-tax net gains within AOCI related to terminated floating-to-fixed treasury locks of $3 million as of March 31, 2014 and $3 million as of December 31, 2013. We recorded $2 million during the first quarter of 2014 as a reduction to interest expense, resulting from the amortization of previously terminated interest rate derivative contracts. As of March 31, 2014, $9 million of pre-tax net gains may be reclassified to earnings within the next twelve months as a reduction to interest expense from amortization of our previously terminated interest rate derivative contracts.
	Counterparty Credit Risk
	We do not have significant concentrations of credit risk arising from our derivative financial instruments, whether from an individual counterparty or a related group of counterparties. We manage our concentration of counterparty credit risk on our derivative instruments by limiting acceptable counterparties to a diversified group of major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to each counterparty, and by actively monitoring their credit ratings and outstanding fair values on an on-going basis. Furthermore, none of our derivative transactions are subject to collateral or other security arrangements and none contain provisions that are dependent on our credit ratings from any credit rating agency.
	We also employ master netting arrangements that reduce our counterparty payment settlement risk on any given maturity date to the net amount of any receipts or payments due between us and the counterparty financial institution. Thus, the maximum loss due to counterparty credit risk is limited to the unrealized gains in such contracts net of any unrealized losses should any of these counterparties fail to perform as contracted. Although these protections do not eliminate concentrations of credit risk, as a result of the above considerations, we do not consider the risk of counterparty default to be significant.
	Fair Value of Derivative Instruments
	The following presents the effect of our derivative instruments designated as cash flow hedges under Topic 815 on our accompanying unaudited condensed consolidated statements of operations during the first quarter of 2014 and 2013 (in millions):
		Amount of Pre-tax				Amount of Pre-tax Gain (Loss) Reclassified from AOCI into Earnings				Location in Statement of
		Gain (Loss)				(Effective Portion)				Operations
		Recognized in OCI
		(Effective Portion)
	Three Months Ended March 31, 2014
	Currency hedge contracts	(21		)		21				Cost of products sold
		$	(21	)		$	21
	Three Months Ended March 31, 2013
	Currency hedge contracts	$	113			$	(6	)		Cost of products sold
		$	113			$	(6	)
	The amount of gain (loss) recognized in earnings related to the ineffective portion of hedging relationships was de minimis for all periods presented.
	Net gains and losses on currency hedge contracts not designated as hedging instruments were offset by net losses and gains from foreign currency transaction exposures, as shown in the following table:
	in millions				Three Months Ended
			Location in Statement of Operations		March 31,
					2014				2013
	Gain (loss) on currency hedge contracts		Other, net		$	21			$	26
	Gain (loss) on foreign currency transaction exposures		Other, net		(24		)		(28		)
	Net foreign currency gain (loss)		Other, net		$	(3	)		$	(2	)
	Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures (Topic 820), by considering the estimated amount we would receive or pay to transfer these instruments at the reporting date and by taking into account current interest rates, foreign currency exchange rates, the creditworthiness of the counterparty for assets, and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. Generally, we use inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of March 31, 2014, we have classified all of our derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by Topic 820, as discussed below, because these observable inputs are available for substantially the full term of our derivative instruments.
	The following are the balances of our derivative assets and liabilities as of March 31, 2014 and December 31, 2013:
			As of
			March 31,				December 31,
	(in millions)	Location in Balance Sheet (1)	2014				2013
	Derivative Assets:
	Designated Hedging Instruments
	Currency hedge contracts	Prepaid and other current assets	$	106			$	117
	Currency hedge contracts	Other long-term assets	88				120
	Interest rate contracts	Prepaid and other current assets	4				1
	Interest rate contracts	Other long-term assets	2				—
			200				238
	Non-Designated Hedging Instruments
	Currency hedge contracts	Prepaid and other current assets	21				27
	Total Derivative Assets		$	221			$	265
	Derivative Liabilities:
	Designated Hedging Instruments
	Currency hedge contracts	Other current liabilities	$	13			$	13
	Currency hedge contracts	Other long-term liabilities	19				19
	Interest rate contracts	Other long-term liabilities	—				8
			32				40
	Non-Designated Hedging Instruments
	Currency hedge contracts	Other current liabilities	24				23
	Total Derivative Liabilities		$	56			$	63
-1	We classify derivative assets and liabilities as current when the remaining term of the derivative contract is one year or less.
Other Fair Value Measurements
Recurring Fair Value Measurements
On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
•	Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
•	Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
•	Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
Assets and liabilities measured at fair value on a recurring basis consist of the following as of March 31, 2014 and December 31, 2013:
	As of March 31, 2014												As of December 31, 2013
(in millions)	Level 1				Level 2				Level 3		Total		Level 1		Level 2		Level 3		Total
Assets
Money market and government funds	$	29			$	—			$	—	$	29	$	38	$	—	$	—	$	38
Currency hedge contracts	—				215				—		215		—		264		—		264
Interest rate contracts	—				6				—		6		—		1		—		1
	$	29			$	221			$	—	$	250	$	38	$	265	$	—	$	303
Liabilities
Currency hedge contracts	$	—			$	56			$	—	$	56	$	—	$	55	$	—	$	55
Accrued contingent consideration	—				—				472		472		—		—		501		501
Interest rate contracts	—				—				—		—		—		8		—		8
	$	—			$	56			$	472	$	528	$	—	$	63	$	501	$	564
Our investments in money market and government funds are generally classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as cash and cash equivalents within our accompanying unaudited condensed consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies.
In addition to $29 million invested in money market and government funds as of March 31, 2014, we had $9 million in short-term time deposits and $153 million in interest bearing and non-interest bearing bank accounts. In addition to $38 million invested in money market and government funds as of December 31, 2013, we had $31 million in short-term deposits and $148 million in interest bearing and non-interest bearing bank accounts.
Our recurring fair value measurements using significant unobservable inputs (Level 3) relate solely to our contingent consideration liabilities. Refer to Note B - Acquisitions for a discussion of the changes in the fair value of our contingent consideration liabilities.
Non-Recurring Fair Value Measurements
We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods subsequent to initial recognition. The fair value of a cost method investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. The aggregate carrying amount of our cost method investments was $26 million as of March 31, 2014 and $20 million as of December 31, 2013.
During the three months ended March 31, 2014, we recorded $55 million of losses to adjust our intangible asset balances to their fair value. During the three months ended March 31, 2013, we recorded $423 million of losses to adjust our goodwill balances to their fair value. Refer to Note D - Goodwill and Other Intangible Assets, for further information related to these charges and significant unobservable inputs (Level 3).
The fair value of our outstanding debt obligations was $4.662 billion as of March 31, 2014 and $4.602 billion as of December 31, 2013, which was determined by using primarily quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy. Refer to Note F – Borrowings and Credit Arrangements for a discussion of our debt obligations.

Borrowings_and_Credit_Arrangem

Borrowings and Credit Arrangements	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
BORROWINGS AND CREDIT ARRANGEMENTS	'
	BORROWINGS AND CREDIT ARRANGEMENTS
	We had total debt of $4.249 billion as of March 31, 2014 and $4.240 billion as of December 31, 2013. The debt maturity schedule for the significant components of our debt obligations as of March 31, 2014 is as follows:
	(in millions)	2014			2015		2016		2017		2018		Thereafter		Total
	Senior notes	$	—		$	400	$	600	$	250	$	600	$	1,950	$	3,800
	Term loan	—			—		80		80		240		—		400
		$	—		$	400	$	680	$	330	$	840	$	1,950	$	4,200
		Note:	The table above does not include unamortized discounts associated with our senior notes, or amounts related to interest rate contracts used to hedge the fair value of certain of our senior notes.
	Revolving Credit Facility
	We maintain a $2.000 billion revolving credit facility, maturing in April 2017, with a global syndicate of commercial banks. Eurodollar and multicurrency loans under this revolving credit facility bear interest at LIBOR plus an interest margin of between 0.875 percent and 1.475 percent, based on our corporate credit ratings and consolidated leverage ratio (1.275 percent as of March 31, 2014). In addition, we are required to pay a facility fee based on our credit ratings, consolidated leverage ratio, and the total amount of revolving credit commitments, regardless of usage, under the agreement (0.225 percent as of March 31, 2014). There were no amounts borrowed under our revolving credit facility as of March 31, 2014 or December 31, 2013.
	Our revolving credit facility agreement in place as of March 31, 2014 requires that we maintain certain financial covenants, as follows:
		Covenant		Actual as of
		Requirement		31-Mar-14
	Maximum leverage ratio (1)	3.5 times		2.4 times
	Minimum interest coverage ratio (2)	3.0 times		5.6 times
	-1	Ratio of total debt to consolidated EBITDA, as defined by the credit agreement, for the preceding four consecutive fiscal quarters.
	-2	Ratio of consolidated EBITDA, as defined by the credit agreement, to interest expense for the preceding four consecutive fiscal quarters.
	The credit agreement provides for an exclusion from the calculation of consolidated EBITDA, as defined by the agreement, through the credit agreement maturity, of any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of March 31, 2014, we had $206 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreement, are excluded from the calculation of consolidated EBITDA and any new debt issued to fund any tax deficiency payments is excluded from consolidated total debt, as defined in the agreement, provided that the sum of any excluded net cash litigation payments and any new debt issued to fund any tax deficiency payments shall not exceed $2.300 billion in the aggregate. As of March 31, 2014, we had approximately $2.183 billion of the combined legal and debt exclusion remaining. As of and through March 31, 2014, we were in compliance with the required covenants.
	Any inability to maintain compliance with these covenants could require us to seek to renegotiate the terms of our credit facilities or seek waivers from compliance with these covenants, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers.
	Term Loan
	We had $400 million outstanding under an unsecured term loan facility as of March 31, 2014 and December 31, 2013. Term loan borrowings under this facility bear interest at LIBOR plus an interest margin of between 1.0 percent and 1.75 percent (currently 1.5 percent), based on our corporate credit ratings and consolidated leverage ratio. The term loan borrowings are payable over a five-year period, with quarterly principal payments of $20 million commencing in the first quarter of 2016 and the remaining principal amount due at the final maturity date in August 2018, and are repayable at any time without premium or penalty. Our term loan facility requires that we comply with certain covenants, including financial covenants with respect to maximum leverage and minimum interest coverage, that are consistent with our revolving credit facility. The maximum leverage ratio requirement is 3.5 times and our actual leverage ratio as of March 31, 2014 is 2.4 times. The minimum interest coverage ratio requirement is 3.0 times and our actual interest coverage ratio as of March 31, 2014 is 5.6 times.
	Senior Notes
	We had senior notes outstanding of $3.800 billion as of March 31, 2014 and December 31, 2013. Our senior notes are publicly registered securities, are redeemable prior to maturity and are not subject to any sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to borrowings under our credit and security facility and liabilities of our subsidiaries (see Other Arrangements below).
	Other Arrangements
	We also maintain a $300 million credit and security facility secured by our U.S. trade receivables maturing in June 2015, subject to further extension. The credit and security facility requires that we maintain a maximum leverage covenant consistent with our revolving credit facility. The maximum leverage ratio requirement is 3.5 times and our actual leverage ratio as of March 31, 2014 is 2.4 times. We had no borrowings outstanding under this facility as of March 31, 2014 and December 31, 2013.
	We have accounts receivable factoring programs in certain European countries that we account for as sales under ASC Topic 860, Transfers and Servicing. These agreements provide for the sale of accounts receivable to third parties, without recourse, of up to approximately $312 million as of March 31, 2014. We have no retained interests in the transferred receivables, other than collection and administrative responsibilities and, once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. We de-recognized $158 million of receivables as of March 31, 2014 at an average interest rate of 3.6 percent, and $146 million as of December 31, 2013 at an average interest rate of 3.3 percent. Within Italy, Spain, Portugal and Greece, the number of days our receivables are outstanding has remained above historical levels. We believe we have adequate allowances for doubtful accounts related to our Italy, Spain, Portugal and Greece accounts receivable; however, we continue to monitor the European economic environment for any collectibility issues related to our outstanding receivables. During the first quarter of 2014, we received cash payments of approximately $80 million related to a government-funded settlement of long outstanding receivables in Spain. As of March 31, 2014, our net receivables in these countries greater than 180 days past due totaled $36 million, of which $17 million were past due greater than 365 days.
	In addition, we have uncommitted credit facilities with a commercial Japanese bank that provide for borrowings, promissory notes discounting and receivables factoring of up to 21.000 billion Japanese yen (approximately $203 million as of March 31, 2014). We de-recognized $144 million of notes receivable as of March 31, 2014 at an average interest rate of 1.5 percent and $147 million of notes receivable as of December 31, 2013 at an average interest rate of 1.8 percent. De-recognized accounts and notes receivable are excluded from trade accounts receivable, net in the accompanying unaudited condensed consolidated balance sheets.
	As of March 31, 2014 and December 31, 2013, we had outstanding letters of credit of $78 million, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of March 31, 2014 and December 31, 2013, none of the beneficiaries had drawn upon the letters of credit or guarantees; accordingly, we did not recognize a related liability for our outstanding letters of credit in our consolidated balance sheets as of March 31, 2014 or December 31, 2013. We believe we will generate sufficient cash from operations to fund these payments and intend to fund these payments without drawing on the letters of credit.

Restructuring_Related_Activiti

Restructuring Related Activities	3 Months Ended
	Mar. 31, 2014
Restructuring and Related Activities [Abstract]	'
RESTRUCTURING-RELATED ACTIVITIES	'
	RESTRUCTURING-RELATED ACTIVITIES
	On an ongoing basis, we monitor the dynamics of the economy, the healthcare industry, and the markets in which we compete. We continue to assess opportunities for improved operational effectiveness and efficiency, and better alignment of expenses with revenues, while preserving our ability to make the investments in research and development projects, capital and our people that we believe are essential to our long-term success. As a result of these assessments, we have undertaken various restructuring initiatives in order to enhance our growth potential and position us for long-term success. These initiatives are described below.
	2014 Restructuring Plan
	On October 22, 2013, the Board of Directors approved, and we committed to, a restructuring initiative (the 2014 Restructuring plan). The 2014 Restructuring plan is intended to build on the progress we have made to address financial pressures in a changing global marketplace, further strengthen our operational effectiveness and efficiency and support new growth investments. Key activities under the plan include continued implementation of our ongoing Plant Network Optimization (PNO) strategy, continued focus on driving operational efficiencies and ongoing business and commercial model changes. The PNO strategy is intended to simplify our manufacturing plant structure by transferring certain production lines among facilities. Other activities involve rationalizing organizational reporting structures to streamline various functions, eliminate bureaucracy, increase productivity and better align resources to business strategies and marketplace dynamics. These activities were initiated in the fourth quarter of 2013 and are expected to be substantially completed by the end of 2015.
	We estimate that the implementation of the 2014 Restructuring plan will result in total pre-tax charges of approximately $175 million to $225 million, and approximately $160 million to $210 million of these charges is estimated to result in cash outlays, of which we have made payments of $17 million to date. We have recorded related costs of $53 million since the inception of the plan, and recorded a portion of these expenses as restructuring charges and the remaining portion through other lines within our consolidated statements of operations.
	The following table provides a summary of our estimates of costs associated with the 2014 Restructuring plan by major type of cost:
	Type of cost	Total estimated amount expected to
		be incurred
	Restructuring charges:
	Termination benefits	$100 million to $120 million
	Other (1)	$5 million to $15 million
	Restructuring-related expenses:
	Other (2)	$70 million to $90 million
		$175 million to $225 million
	(1) Consists primarily of consultant fees and costs associated with contractual cancellations.
	(2) Comprised of other costs directly related to the 2014 Restructuring plan, including program management, accelerated depreciation, and costs to transfer product lines among facilities.
	2011 Restructuring Plan
	On July 26, 2011, our Board of Directors approved, and we committed to, a restructuring initiative (the 2011 Restructuring plan) designed to strengthen operational effectiveness and efficiencies, increase competitiveness and support new investments, thereby increasing shareholder value. Key activities under the 2011 Restructuring plan included standardizing and automating certain processes and activities; relocating select administrative and functional activities; rationalizing organizational reporting structures; leveraging preferred vendors; and other efforts to eliminate inefficiency. Among these efforts, we expanded our ability to deliver best-in-class global shared services for certain functions and divisions at several locations in emerging markets. This action was intended to enable us to grow our global commercial presence in key geographies and take advantage of many cost-reducing and productivity-enhancing opportunities. In addition, we undertook efforts to streamline various corporate functions, eliminate bureaucracy, increase productivity and better align corporate resources to our key business strategies. On January 25, 2013, our Board of Directors approved, and we committed to, an expansion of the 2011 Restructuring plan (the Expansion). The Expansion was intended to further strengthen our operational effectiveness and efficiencies and support new investments. Activities under the 2011 Restructuring plan were initiated in the third quarter of 2011 and all activities, including those related to the Expansion, were substantially completed by the end of 2013.
	The 2011 Restructuring plan, including the Expansion, is estimated to result in total pre-tax charges of approximately $289 million to $292 million, and approximately $280 million to $283 million of these charges is estimated to result in cash outlays, of which we have made payments of $280 million to date. We have recorded related costs of $289 million since the inception of the plan, and recorded a portion of these expenses as restructuring charges and the remaining portion through other lines within our consolidated statements of operations.
	The following provides a summary of our expected total costs associated with the 2011 Restructuring plan, including the Expansion, by major type of cost:
	Type of cost	Total estimated amount expected to
		be incurred
	Restructuring charges:
	Termination benefits	$137 million to $140 million
	Other (1)	$114 million
	Restructuring-related expenses:
	Other (2)	$38 million
		$289 million to $292 million
	-1	Includes primarily consulting fees, gains and losses on disposals of fixed assets and costs associated with contractual cancellations.
	-2	Comprised of other costs directly related to the 2011 Restructuring plan, including the Expansion, such as program management, accelerated depreciation, retention and infrastructure-related costs.
	Plant Network Optimization Program
	In January 2009, our Board of Directors approved, and we committed to, a Plant Network Optimization program, intended to simplify our manufacturing plant structure by transferring certain production lines among facilities and by closing certain other facilities. The program was intended to improve our overall gross profit margins. Activities under the Plant Network Optimization program were initiated in the first quarter of 2009 and were substantially completed during 2012.
	The Plant Network Optimization program resulted in total pre-tax charges of $126 million, and resulted in cash outlays of $103 million. We recorded a portion of these expenses as restructuring charges and the remaining portion through cost of products sold within our unaudited condensed consolidated statements of operations.
	The following provides a summary of our costs associated with the Plant Network Optimization program by major type of cost:
	Type of cost	Total amount incurred
	Restructuring charges:
	Termination benefits	$30 million
	Restructuring-related expenses:
	Accelerated depreciation	$22 million
	Transfer costs (1)	$74 million
		$126 million
	-1	Consists primarily of costs to transfer product lines among facilities, including costs of transfer teams, freight, idle facility and product line validations.
	In the aggregate, we recorded net restructuring charges pursuant to our restructuring plans of $20 million and $10 million in the first quarter of 2014 and 2013, respectively. During the first quarter of 2013, our other restructuring charges were partially offset by a $19 million gain recognized on the sale of our Natick, Massachusetts headquarters. In addition, we recorded expenses within other lines of our accompanying unaudited condensed consolidated statements of operations related to our restructuring initiatives of $8 million in the first quarter of 2014 and $5 million in the first quarter of 2013.
	The following presents these costs (credits) by major type and line item within our accompanying unaudited condensed consolidated statements of operations, as well as by program:
	Three Months Ended March 31, 2014
	(in millions)	Termination				Accelerated				Transfer				Fixed Asset			Other		Total
		Benefits				Depreciation				Costs				Write-offs
	Restructuring charges	$	11			$	—			$	—			$	—		$	9	$	20
	Restructuring-related expenses:
	Cost of products sold	—				—				2				—			—		2
	Selling, general and administrative expenses	—				1				—				—			5		6
		—				1				2				—			5		8
		$	11			$	1			$	2			$	—		$	14	$	28
	(in millions)	Termination				Accelerated				Transfer				Fixed Asset			Other		Total
		Benefits				Depreciation				Costs				Write-offs
	2014 Restructuring plan	$	9			$	1			$	2			$	—		$	11	$	23
	2011 Restructuring plan (including the Expansion)	2				—				—				—			3		5
		$	11			$	1			$	2			$	—		$	14	$	28
	Three Months Ended March 31, 2013
	(in millions)	Termination				Accelerated				Transfer				Net Gain on Fixed Asset Disposals			Other		Total
		Benefits				Depreciation				Costs
	Restructuring charges	$	8			$	—			$	—			$	(17	)	$	19	$	10
	Restructuring-related expenses:
Cost of products sold	—				—				—				—			—		—
Selling, general and administrative expenses	—				1				—				—			4		5
	—				1				—				—			4		5
	$	8			$	1			$	—			$	(17	)	$	23	$	15
(in millions)	Termination				Accelerated				Transfer				Net Gain on Fixed Asset Disposals			Other		Total
	Benefits				Depreciation				Costs
2011 Restructuring plan (including the Expansion)	$	10			$	1			$	—			$	(17	)	$	23	$	17
Plant Network Optimization program	(2		)		—				—				—			—		(2		)
	$	8			$	1			$	—			$	(17	)	$	23	$	15
Termination benefits represent amounts incurred pursuant to our on-going benefit arrangements and amounts for “one-time” involuntary termination benefits, and have been recorded in accordance with ASC Topic 712, Compensation – Non-retirement Postemployment Benefits and ASC Topic 420, Exit or Disposal Cost Obligations (Topic 420). We expect to record additional termination benefits related to our restructuring initiatives in 2014 when we identify with more specificity the job classifications, functions and locations of the remaining head count to be eliminated. Other restructuring costs, which represent primarily consulting fees, are being recorded as incurred in accordance with Topic 420. Accelerated depreciation is being recorded over the adjusted remaining useful life of the related assets, and production line transfer costs are being recorded as incurred.
As of March 31, 2014, we have incurred cumulative restructuring charges related to our 2014 Restructuring plan, 2011 Restructuring plan (including the Expansion), and Plant Network Optimization program of $324 million and restructuring-related costs of $144 million since we committed to each plan. The following presents these costs by major type and by plan:
The following presents these costs by major type and by plan:
(in millions)	2014				2011				Plant				Total
	Restructuring				Restructuring				Network
	plan				plan (including the Expansion)				Optimization program
Termination benefits	$	37			$	138			$	30			$	205
Fixed asset write-offs	—				(1		)		—				(1		)
Other	7				113				—				120
Total restructuring charges	44				250				30				324
Accelerated depreciation	1				5				22				28
Transfer costs	2				—				74				76
Other	6				34				—				40
Restructuring-related expenses	9				39				96				144
	$	53			$	289			$	126			$	468
We made cash payments of $29 million in the first quarter of 2014 associated with restructuring initiatives pursuant to these plans, and as of March 31, 2014, we had made total cash payments of $400 million related to our 2014 Restructuring plan, 2011 Restructuring plan (including the Expansion), and Plant Network Optimization program since committing to each plan. These payments were made using cash generated from operations, and are comprised of the following:
(in millions)	2014				2011				Plant				Total
	Restructuring				Restructuring				Network
	plan				plan (including the Expansion)				Optimization program
Three Months Ended March 31, 2014
Termination benefits	$	6			$	7			$	—			$	13
Transfer costs	2				—				—				2
Other	9				5				—				14
	$	17			$	12			$	—			$	29
Program to Date
Termination benefits	$	6			$	131			$	30			$	167
Transfer costs	2				—				73				75
Other	9				149				—				158
	$	17			$	280			$	103			$	400
Our restructuring liability is primarily comprised of accruals for termination benefits. The following is a rollforward of the termination benefit liability associated with our 2014 Restructuring plan and 2011 Restructuring plan (including the Expansion), which is reported as a component of accrued expenses included in our accompanying unaudited condensed balance sheets:
(in millions)		2014				2011				Total
		Restructuring				Restructuring
		plan				plan (including the Expansion)
Accrued as of December 31, 2013		$	29			$	12			$	41
Charges (credits)		9				2				11
Cash payments		(6		)		(7		)		(13		)
Other adjustments		—				—				—
Accrued as of March 31, 2014		$	32			$	7			$	39
In addition to our accrual for termination benefits, we had an $8 million liability as of March 31, 2014 and December 31, 2013 for other restructuring-related items.

Supplemental_Balance_Sheet_Inf

Supplemental Balance Sheet Information	3 Months Ended
	Mar. 31, 2014
Supplemental Balance Sheet Information [Abstract]	'
Supplemental Balance Sheet Disclosures	'
	SUPPLEMENTAL BALANCE SHEET INFORMATION
	Components of selected captions in our accompanying unaudited condensed consolidated balance sheets are as follows:
	Trade accounts receivable, net
		As of
	(in millions)	31-Mar-14			31-Dec-13
	Accounts receivable	$	1,322		$	1,419
	Less: allowance for doubtful accounts	(75		)	(81		)
	Less: allowance for sales returns	(30		)	(31		)
		$	1,217		$	1,307
	The following is a rollforward of our allowance for doubtful accounts for the first quarter of 2014 and 2013:
		Three Months Ended
		March 31,
	(in millions)	2014			2013
	Beginning balance	$	81		$	88
	Charges to expenses	(2		)	3
	Utilization of allowances	(4		)	(5		)
	Ending balance	$	75		$	86
	Inventories
		As of
	(in millions)	31-Mar-14			31-Dec-13
	Finished goods	$	611		$	598
	Work-in-process	116			90
	Raw materials	199			209
		$	926		$	897
	Property, plant and equipment, net
		As of
	(in millions)	31-Mar-14			31-Dec-13
	Land	$	81		$	81
	Buildings and improvements	919			917
	Equipment, furniture and fixtures	2,492			2,461
	Capital in progress	234			211
		3,726			3,670
	Less: accumulated depreciation	2,187			2,124
		$	1,539		$	1,546
	Depreciation expense was $65 million for the first quarter of 2014 and $61 million for the first quarter of 2013.
	Accrued expenses
		As of
	(in millions)	31-Mar-14			31-Dec-13
	Payroll and related liabilities	$	370		$	488
	Accrued contingent consideration	228			148
	Legal reserves	98			84
	Other	579			628
		$	1,275		$	1,348
	Other long-term liabilities
		As of
	(in millions)	31-Mar-14			31-Dec-13
	Accrued income taxes	$	1,231		$	1,283
	Accrued contingent consideration	244			353
	Legal reserves	498			523
	Other long-term liabilities	425			410
		$	2,398		$	2,569
	Accrued warranties
	We offer warranties on certain of our product offerings. The majority of our warranty liability as of March 31, 2014 related to implantable devices offered by our CRM business, which include defibrillator and pacemaker systems. Our CRM products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant, and a partial warranty over the substantial remainder of the useful life of the product. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim, and record a liability equal to these estimated costs as cost of products sold at the time the product sale occurs. We reassess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary. The current portion of our warranty accrual is included in other accrued expenses in the table above and the non-current portion of our warranty accrual is included in other long-term liabilities in the table above. Changes in our product warranty accrual during the first three months of 2014 and 2013 consisted of the following (in millions):
		Three Months Ended
		March 31,
		2014			2013
	Beginning Balance	$	28		$	26
	Provision	4			4
	Settlements/reversals	(3		)	(3		)
	Ending Balance	$	29		$	27

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	INCOME TAXES
	Our effective tax rates from continuing operations for the three months ended March 31, 2014 and March 31, 2013, were 8.9% and 10.2%, respectively. The change in our reported tax rate for the first quarter of 2014, as compared to the same period in 2013, relates primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate and the impact of certain discrete tax items, including intangible asset impairment charges, acquisition- and divestiture-related items, and litigation- and restructuring-related items. In addition, our reported tax rate in the first quarter of 2013 was also impacted by discrete tax items that primarily related to the reinstatement of tax legislation that was retroactively applied, offset in part by the resolution of uncertain tax positions related to audit settlements.
	As of March 31, 2014, we had $1.034 billion of gross unrecognized tax benefits, of which a net $922 million, if recognized, would affect our effective tax rate. As of December 31, 2013, we had $1.069 billion of gross unrecognized tax benefits, of which a net $939 million, if recognized, would affect our effective tax rate.
	During the three months ended March 31, 2014, we received a Revenue Agent Report from the Internal Revenue Services (IRS) reflecting significant proposed audit adjustments for our 2008, 2009 and 2010 tax years based upon the same transfer pricing methodologies that are currently being contested in U.S. Tax Court for our tax years from 2001 to 2008. As with the prior years, we disagree with the transfer pricing methodologies being applied by the IRS and we expect to contest any adjustments received through applicable IRS and judicial procedures, as appropriate. We believe that our income tax reserves associated with these matters are adequate as of March 31, 2014; however, final resolution is uncertain and could have a material impact on our financial condition, results of operations, or cash flows. During the three months ended March 31, 2014, there were no other material changes to significant unresolved matters with the IRS or foreign tax authorities from what we disclosed in our 2013 Annual Report filed on Form 10-K.
	We recognize interest and penalties related to income taxes as a component of income tax expense. We had $416 million accrued for gross interest and penalties as of March 31, 2014 and $402 million as of December 31, 2013. The increase in gross interest and penalties was $14 million, recognized in our unaudited condensed consolidated statements of operations. We recognized net tax expense related to interest of $9 million during the first quarter of 2014 and $9 million during the first quarter of 2013.
	It is reasonably possible that within the next 12 months we will resolve multiple issues including transfer pricing and transactional-related issues with foreign, federal and state taxing authorities, in which case we could record a reduction in our balance of unrecognized tax benefits of up to approximately $15 million.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	COMMITMENTS AND CONTINGENCIES
	The medical device market in which we primarily participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These forces frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.
	During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable legal rulings in several other matters; however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.
	In the normal course of business, product liability, securities and commercial claims are asserted against us. Similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation, and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our financial position, results of operations and/or liquidity.
	In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.
	We record losses for claims in excess of the limits of purchased insurance in earnings at the time and to the extent they are probable and estimable. In accordance with ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for general product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.
	Our accrual for legal matters that are probable and estimable was $596 million as of March 31, 2014 and $607 million as of December 31, 2013, and includes estimated costs of settlement, damages and defense. The decrease in our legal accrual was primarily due to a net $7 million credit recorded during the first quarter of 2014. During the first quarter of 2013 we recorded $130 million of litigation-related charges. We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our debt covenants.
	In management's opinion, we are not currently involved in any legal proceedings other than those disclosed in our 2013 Annual Report filed on Form 10-K and those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be estimated.
	Patent Litigation
	On May 16, 2013, Vascular Solutions, Inc. filed suit against us, alleging that our Guidezilla™ guide extension catheter infringes three U.S. patents owned by Vascular Solutions.  The suit was filed in the U.S. District Court for the District of Minnesota seeking monetary and injunctive relief.  On May 28, 2013, Vascular Solutions filed an amended complaint adding an allegation of copyright infringement.  On June 10, 2013, Vascular Solutions filed a motion requesting a preliminary injunction.  On July 11, 2013, we answered the amended complaint and filed a counterclaim against Vascular Solutions, alleging that its Guideliner™ guide extension catheter infringes a U.S. patent owned by us. On December 12, 2013, the District Court granted the motion for a preliminary injunction and on December 26, 2013, we filed an appeal. On April 15, 2014, the Court of Appeals for the Federal Circuit vacated the preliminary injunction.
	On September 23, 2013, Kardiametrics, LLC filed a complaint in the United States District Court for the District of Delaware alleging that the sale of our FilterWire EZ Embolic Protection System, Sterling balloon catheters, Carotid NexStent and Carotid WallStent products infringe two patents owned by Kardiametrics. On January 24, 2014, we filed a motion to dismiss the case or, in the alternative, to stay the case pending an arbitration. On February 18, 2014, Kardiametrics dismissed its original complaint and filed a new complaint. On March 14, 2014, we filed a motion to dismiss the new case or, in the alternative, to stay the new case pending an arbitration.
	On February 18, 2014, Atlas IP, LLC filed a complaint in the United States District Court for the Southern District of Florida alleging that the sale of our LATITUDE® Patient Management System and implantable devices that communicate with the LATITUDE® device infringe a patent owned by Atlas.
	Product Liability Litigation
	Fewer than ten individual lawsuits remain pending in various state and federal jurisdictions against Guidant Corporation (Guidant) alleging personal injuries associated with defibrillators or pacemakers involved in certain 2005 and 2006 product communications. Further, we are aware of approximately 30 Guidant product liability lawsuits pending in international jurisdictions associated with defibrillators or pacemakers, including devices involved in the 2005 and 2006 product communications. Six of these suits are pending in Canada and were filed as class actions, four of which are stayed pending the outcome of two lead class actions. On April 10, 2008, the Justice of Ontario Court certified a class of persons in whom defibrillators were implanted in Canada and a class of family members with derivative claims. On May 8, 2009, the Justice of Ontario Court certified a class of persons in whom pacemakers were implanted in Canada and a class of family members with derivative claims. In each case, these matters generally seek monetary damages from us. The parties in the defibrillator class action have reached an agreement in principle to settle the matter for approximately $3 million. The presiding judge verbally approved the settlement at a hearing on March 24, 2014.
	As of May 7, 2014, there were over 20,000 product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse pending against us. The cases are pending in various federal and state courts in the United States and include eight putative class actions. There were also over ten cases in Canada, inclusive of three putative class actions. Additionally, as of May 7, 2014, there were three claims in the United Kingdom. Generally, the plaintiffs allege personal injury associated with use of our transvaginal surgical mesh products. The plaintiffs assert design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims.  Over 1,700 of the cases have been specially assigned to one judge in state court in Massachusetts. On February 7, 2012, the Judicial Panel on Multi-District Litigation (MDL) established MDL-2326 in the U.S. District Court for the Southern District of West Virginia and transferred the federal court transvaginal surgical mesh cases to MDL-2326 for coordinated pretrial proceedings. In addition, in October 2012, the Attorney General for the State of California informed us that their office and certain other state attorneys general offices intended to initiate a civil investigation into our sale of transvaginal surgical mesh products. During the fourth quarter of 2013, we received written discovery requests from certain state attorneys general offices. We have responded to those requests. We have established a product liability accrual for known and estimated future cases and claims asserted against us as well as costs of defense thereof associated with our transvaginal surgical mesh products. While we believe that our accrual associated with this matter is adequate, changes to this accrual may be required in the future as additional information becomes available. We intend to vigorously contest the cases and claims asserted against us; however, the final resolution is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity.
	Governmental Investigations and Qui Tam Matters
	On May 5, 2014, we were served with a subpoena from the U.S. Department of Health and Human Services, Office of the Inspector General.  The subpoena seeks information relating to the launch of the Cognis and Teligen line of devices in 2008, the performance of those devices from 2007 to 2009, and the operation of the Physician Guided Learning Program.  We are cooperating with this request.
	Other Proceedings
	On October 5, 2007, Dr. Tassilo Bonzel filed a complaint against Pfizer, Inc. and our Schneider subsidiaries and us in the District Court in Kassel, Germany alleging that a 1995 license agreement related to a catheter patent is invalid under German law and seeking monetary damages. In June 2009, the District Court dismissed all but one of Dr. Bonzel's claims and in October 2009, he added new claims. We opposed the addition of the new claims. The District Court ordered Dr. Bonzel to select the claims he would pursue and in January 2011, he made that selection. A hearing was held on March 28, 2014.
	On April 24, 2014, Dr. Qingsheng Zhu and Dr. Julio Spinelli, acting jointly on behalf of the stockholder representative committee of Action Medical, Inc. (Action Medical), filed a lawsuit against us and our subsidiary, Cardiac Pacemakers, Inc. (CPI), in the U.S. District Court for the District of Delaware.  The stockholder representatives allege that we and CPI breached a contractual duty to pursue development and commercialization of certain patented heart pacing methods and devices and to return certain patents.
	Refer to Note I - Income Taxes for information regarding our tax litigation.
	Matters Concluded Since December 31, 2013
	On February 1, 2008, Wyeth Corporation (Wyeth) and Cordis Corporation filed an amended complaint for patent infringement against Abbott Laboratories, adding us and Boston Scientific Scimed, Inc. as additional defendants to the complaint. The suit alleged that the PROMUS® coronary stent system, supplied to us by Abbott, infringes three U.S. patents owned by Wyeth and licensed to Cordis. The suit was filed in the U.S. District Court for the District of New Jersey seeking monetary and injunctive relief. Wyeth and Cordis subsequently withdrew their infringement claim as to one of the patents, and the District Court found the remaining two patents invalid. Wyeth and Cordis filed an appeal and, on June 26, 2013, the Court of Appeals for the Federal Circuit affirmed the District Court’s judgment in favor of Boston Scientific. On October 13, 2013, Wyeth’s motion for rehearing or rehearing en banc was denied. The deadline for further appeals lapsed on January 13, 2014.
	On May 25, 2010, G. David Jang, M.D. filed suit against Boston Scientific Scimed, Inc. and us alleging breach of contract relating to certain patent rights covering stent technology. In October 2011, the U.S. District Court for the District of Delaware entered judgment in favor of us on the pleadings. Dr. Jang filed an appeal on August 28, 2012. On September 5, 2013, the Court of Appeals for the Third Circuit vacated the ruling and remanded the case to the District Court.  On March 31, 2014, the parties entered into a confidential settlement agreement.  On April 2, 2014, the case was dismissed.

Weighted_Average_Shares_Outsta

Weighted Average Shares Outstanding	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Weighted Average Number Of Shares Outstanding [Text Block]	'
	WEIGHTED AVERAGE SHARES OUTSTANDING
		Three Months Ended
		March 31,
	(in millions)	2014	2013
	Weighted average shares outstanding - basic	1,321.70	1,351.90
	Net effect of common stock equivalents	27.5	—	*
	Weighted average shares outstanding - assuming dilution	1,349.20	1,351.90
	* We generated a net loss in the first quarter of 2013. Our weighted-average shares outstanding for earnings per share calculations
	exclude common stock equivalents of 12.8 million for the first quarter of 2013 due to our net loss position in this period.
	Weighted average shares outstanding, assuming dilution, excludes the impact of 12 million stock options for the first quarter of 2014 and 48 million stock options for the first quarter of 2013, due to the exercise prices of these stock options being greater than the average fair market value of our common stock during the period.
	We issued approximately 10 million shares of our common stock in the first quarters of 2014 and eight million shares of our common stock in the first quarter of 2013, following the exercise or vesting of underlying stock options or deferred stock units, or purchases under our employee stock purchase plans. We repurchased approximately 10 million shares of our common stock during the first quarter of 2014 for approximately $125 million and 13 million shares of our common stock during the first quarter of 2013 for approximately $100 million, pursuant to our authorized repurchase programs as discussed in Note L – Stockholders' Equity to our audited financial statements contained in Item 8 of our 2013 Annual Report filed on Form 10-K.

Segment_Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
SEGMENT REPORTING	'
	SEGMENT REPORTING
	Effective as of January 1, 2013, we reorganized our business from geographic regions to fully operationalized global business units. Following the reorganization, based on information regularly reviewed by our chief operating decision maker, we have three reportable segments comprised of: Cardiovascular, Rhythm Management, and MedSurg. Our reportable segments represent an aggregate of operating segments.
	Each of our reportable segments generates revenues from the sale of medical devices. We measure and evaluate our reportable segments based on segment net sales and operating income, excluding the impact of changes in foreign currency and sales from divested businesses. Sales generated from reportable segments and divested businesses, as well as operating results of reportable segments and corporate expenses, are based on internally-derived standard currency exchange rates, which may differ from year to year, and do not include intersegment profits. We restated segment information for the prior period based on standard currency exchange rates used for the current period in order to remove the impact of foreign currency exchange fluctuation and for the realignment of certain product lines from Endoscopy to Peripheral Interventions as of January 1, 2014. We exclude from segment operating income certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker considers to be non-recurring and/or non-operational, such as amounts related to goodwill and other intangible asset impairment charges; acquisition-, divestiture-, restructuring- and litigation-related charges and credits; and amortization expense. Although we exclude these amounts from segment operating income, they are included in reported consolidated operating income (loss) and are included in the reconciliation below.
	A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying unaudited condensed consolidated statements of operations is as follows:
		Three Months Ended
		March 31,
	(in millions)	2014			2013
					(restated)
	Net sales
	Interventional Cardiology	$	501		$	498
	Peripheral Interventions	204			193
	Cardiovascular	705			691
	Cardiac Rhythm Management	464			475
	Electrophysiology	58			34
	Rhythm Management	522			509
	Endoscopy	316			300
	Urology and Women's Health	126			117
	Neuromodulation	109			89
	MedSurg	551			506
	Net sales allocated to reportable segments	1,778			1,706
	Sales generated from divested businesses	2			36
	Impact of foreign currency fluctuations	(6		)	19
		$	1,774		$	1,761
	Income (loss) before income taxes
	Cardiovascular	$	171		$	158
	Rhythm Management	66			57
	MedSurg	168			140
	Operating income allocated to reportable segments	405			355
	Corporate expenses and currency exchange	(50		)	(42		)
	Goodwill and other intangible asset impairment charges; and acquisition-, divestiture-, restructuring-, and litigation related charges or credits	(49		)	(540		)
	Amortization expense	(109		)	(103		)
	Operating income (loss)	197			(330		)
	Other expense, net	(51		)	(64		)
	Income (loss) before income taxes	$	146		$	(394	)

Changes_in_Other_Comprehensive

Changes in Other Comprehensive Income (Notes)	3 Months Ended
	Mar. 31, 2014
Changes in Other Comprehensive Income [Abstract]	'
Comprehensive Income (Loss) Note [Text Block]	'
	CHANGES IN OTHER COMPREHENSIVE INCOME
	The following table provides the reclassifications out of other comprehensive income for the three months ended March 31, 2014 and March 31, 2013. Amounts in the chart below are presented net of tax.
	Three Months Ended March 31, 2014
	(in millions)	Foreign currency translation adjustments	Unrealized gains/losses on derivative financial instruments	Defined benefit pension items / Other	Total
	Balance as of December 31, 2013	($16)	$141	($19)	$106
	Other comprehensive income (loss) before reclassifications	-6	-14	-1	-21
	Amounts reclassified from accumulated other comprehensive income	—	-13	—	-13
	Net current-period other comprehensive income	-6	-27	-1	-34
	Balance as of March 31, 2014	($22)	$114	($20)	$72
	Three Months Ended March 31, 2013
	(in millions)	Foreign currency translation adjustments	Unrealized gains/losses on derivative financial instruments	Defined benefit pension items / Other	Total
	Balance as of December 31, 2012	($26)	$34	($41)	($33)
	Other comprehensive income (loss) before reclassifications	3	71	—	74
	Amounts reclassified from accumulated other comprehensive income	—	4	—	4
	Net current-period other comprehensive income	3	75	—	78
	Balance as of March 31, 2013	($23)	$109	($41)	$45
	The income tax impact of the amounts in other comprehensive income for unrealized gains/losses on derivative financial instruments before reclassifications was a benefit of $7 million in the first quarter of 2014 and an expense of $43 million in the first quarter of 2013. The gains and losses on derivative financial instruments reclassified were reduced by income tax impacts of $8 million in the first quarter of 2014 and $2 million in the first quarter of 2013. Refer to Note E – Fair Value Measurements for further detail on the reclassifications related to derivatives.

New_Accounting_Pronouncements

New Accounting Pronouncements	3 Months Ended
	Mar. 31, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
NEW ACCOUNTING PRONOUNCEMENTS	'
	NEW ACCOUNTING PRONOUNCEMENTS
	Standards Implemented
	ASC Update No. 2013-11
	In July 2013, the FASB issued ASC Update No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. Update No. 2013-11 requires that entities present an unrecognized tax benefit, or portion of an unrecognized tax benefit, as a reduction to a deferred tax asset in the financial statements for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, with certain exceptions. We were required to adopt Update No. 2013-11 for our first quarter ending March 31, 2014. Update No. 2013-11 is related to presentation only and its adoption did not impact our results of operations or financial position.
	Standards to be Implemented
	ASC Update No. 2014-08
	In April 2014, the FASB issued ASC Update No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Update No. 2014-08 changed the criteria for reporting discontinued operations and enhancing convergence of the FASB's and the International Accounting Standard Board's (IASB) reporting requirements for discontinued operations. We are required to apply this amendment, prospectively to: (1) all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014 and interim periods within those years and (2) all businesses or nonprofit activities that, on acquisition, are classified as held for sale that occur within annual periods beginning on or after December 15, 2014 and interim periods within those years.

Accounting_Policies_Policies

Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Legal Costs, Policy [Policy Text Block]	'
	We record losses for claims in excess of the limits of purchased insurance in earnings at the time and to the extent they are probable and estimable. In accordance with ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for general product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.
ASC Topic 820, Fair Value Measurements and Disclosures	'
	We determine the fair value of our derivative instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures (Topic 820), by considering the estimated amount we would receive or pay to transfer these instruments at the reporting date and by taking into account current interest rates, foreign currency exchange rates, the creditworthiness of the counterparty for assets, and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. Generally, we use inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means.
ASC Topic 815, Derivatives and Hedging	'
	We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with ASC Topic 815, Derivatives and Hedging (Topic 815). In accordance with Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship. Our derivative instruments do not subject our earnings or cash flows to material risk, as gains and losses on these derivatives generally offset losses and gains on the item being hedged. We do not enter into derivative transactions for speculative purposes and we do not have any non-derivative instruments that are designated as hedging instruments pursuant to Topic 815.
ASC Topic 712, Compensation - Non-retirement Postemployment Benefits and ASC Topic 420, Exit or Disposal Cost Obligations	'
	Termination benefits represent amounts incurred pursuant to our on-going benefit arrangements and amounts for “one-time” involuntary termination benefits, and have been recorded in accordance with ASC Topic 712, Compensation – Non-retirement Postemployment Benefits and ASC Topic 420, Exit or Disposal Cost Obligations (Topic 420). We expect to record additional termination benefits related to our restructuring initiatives in 2014 when we identify with more specificity the job classifications, functions and locations of the remaining head count to be eliminated. Other restructuring costs, which represent primarily consulting fees, are being recorded as incurred in accordance with Topic 420. Accelerated depreciation is being recorded over the adjusted remaining useful life of the related assets, and production line transfer costs are being recorded as incurred.
Subsequent Events, Policy [Policy Text Block]	'
	Subsequent Events
	We evaluate events occurring after the date of our most recent accompanying unaudited condensed consolidated balance sheets for potential recognition or disclosure in our financial statements. We did not identify any material subsequent events requiring adjustment to our accompanying unaudited condensed consolidated financial statements (recognized subsequent events) for the three month period ended March 31, 2014. Those items requiring disclosure (unrecognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note B - Acquisitions and Note J - Commitments and Contingencies for more information.
ASC Update No. 2013-11, Income Taxes (Topic 740) [Policy Text Block]	'
	ASC Update No. 2013-11
	In July 2013, the FASB issued ASC Update No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. Update No. 2013-11 requires that entities present an unrecognized tax benefit, or portion of an unrecognized tax benefit, as a reduction to a deferred tax asset in the financial statements for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, with certain exceptions. We were required to adopt Update No. 2013-11 for our first quarter ending March 31, 2014. Update No. 2013-11 is related to presentation only and its adoption did not impact our results of operations or financial position.
ASC Update No. 2014-08, Presentation of Financial Statements (Topic 205) and Property Plant and Equipment (Topic 360) [Policy Text Block]	'
	ASC Update No. 2014-08
	In April 2014, the FASB issued ASC Update No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Update No. 2014-08 changed the criteria for reporting discontinued operations and enhancing convergence of the FASB's and the International Accounting Standard Board's (IASB) reporting requirements for discontinued operations. We are required to apply this amendment, prospectively to: (1) all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014 and interim periods within those years and (2) all businesses or nonprofit activities that, on acquisition, are classified as held for sale that occur within annual periods beginning on or after December 15, 2014 and interim periods within those years.

Acquisitions_Tables

Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Rollforward of Fair Value of Contingent Consideration [Table Text Block]	'
	Changes in the fair value of our contingent consideration liability were as follows (in millions):
	Balance as of December 31, 2013	$	(501	)
	Amounts recorded related to new acquisitions	(3		)
	Other amounts recorded related to prior acquisitions	(2		)
	Net fair value adjustments	22
	Payments made	12
	Balance as of March 31, 2014	$	(472	)
Description of unobservable inputs used in Level 3 fair value measurements [Table Text Block]	'
	The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:
	Contingent Consideration Liability	Fair Value as of March 31, 2014	Valuation Technique	Unobservable Input	Range
	R&D, Regulatory and Commercialization-based Milestones	$87 million	Probability Weighted Discounted Cash Flow	Discount Rate	0.7%-1.4%
				Probability of Payment	85% - 95%
				Projected Year of Payment	2014 - 2015
	Revenue-based Payments	$131 million	Discounted Cash Flow	Discount Rate	11.5% - 15%
				Probability of Payment	0% - 100%
				Projected Year of Payment	2014 - 2018
		$254 million	Monte Carlo	Revenue Volatility	13% - 19%
				Risk Free Rate	LIBOR Term Structure
				Projected Year of Payment	2014-2018
	The nonrecurring Level 3 fair value measurements of our intangible asset impairment analysis included the following significant unobservable inputs:
	Intangible Asset	Valuation Date	Fair Value	Valuation Technique	Unobservable Input	Rate
	In-Process R&D	31-Mar-14	$6 million	Income Approach - Excess Earnings Method	Discount Rate	20%
	Core Technology	31-Mar-14	$64 million	Income Approach - Excess Earnings Method	Discount Rate	15%

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets Goodwill (Tables)	3 Months Ended
	Mar. 31, 2014
Note D - Goodwill and Other Intangible Assets [Abstract]	'
Goodwill	'
	The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill as of March 31, 2014 and December 31, 2013 are as follows:
			As of
			March 31, 2014								December 31, 2013
			Gross Carrying				Accumulated				Gross Carrying				Accumulated
							Amortization/								Amortization/
	(in millions)		Amount				Write-offs				Amount				Write-offs
	Amortizable intangible assets
	Technology-related		$	8,232			$	(3,431	)		$	8,272			$	(3,342	)
	Patents		521				(332		)		513				(326		)
	Other intangible assets		846				(493		)		845				(479		)
			$	9,599			$	(4,256	)		$	9,630			$	(4,147	)
	Unamortizable intangible assets
	Goodwill		$	15,597			$	(9,900	)		$	15,593			$	(9,900	)
	Technology-related		197				—				197				—
			$	15,794			$	(9,900	)		$	15,790			$	(9,900	)
Schedule of Goodwill [Table Text Block]	'
	The following represents our goodwill balance by global reportable segment:
	(in millions)		Cardiovascular				Rhythm Management				MedSurg				Total
	Balance as of December 31, 2013		$	3,252			$	294			$	2,147			$	5,693
	Purchase price adjustments		—				(2		)		—				(2		)
	Goodwill acquired		—				—				6				6
	Goodwill written off		—				—				—				—
	Other changes in carrying amount *		7				—				(7		)		—
	Balance as of March 31, 2014		$	3,259			$	292			$	2,146			$	5,697
	The following is a rollforward of accumulated goodwill write-offs by global reportable segment:
	(in millions)	Cardiovascular				Rhythm Management				MedSurg				Total
	Accumulated write-offs as of December 31, 2013	$	(1,479	)		$	(6,960	)		$	(1,461	)		$	(9,900	)
	Goodwill written off	—				—				—				—
	Accumulated write-offs as of March 31, 2014	$	(1,479	)		$	(6,960	)		$	(1,461	)		$	(9,900	)
Description of unobservable inputs used in Level 3 fair value measurements [Table Text Block]	'
	The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:
	Contingent Consideration Liability	Fair Value as of March 31, 2014	Valuation Technique	Unobservable Input	Range
	R&D, Regulatory and Commercialization-based Milestones	$87 million	Probability Weighted Discounted Cash Flow	Discount Rate	0.7%-1.4%
				Probability of Payment	85% - 95%
				Projected Year of Payment	2014 - 2015
	Revenue-based Payments	$131 million	Discounted Cash Flow	Discount Rate	11.5% - 15%
				Probability of Payment	0% - 100%
				Projected Year of Payment	2014 - 2018
		$254 million	Monte Carlo	Revenue Volatility	13% - 19%
				Risk Free Rate	LIBOR Term Structure
				Projected Year of Payment	2014-2018
	The nonrecurring Level 3 fair value measurements of our intangible asset impairment analysis included the following significant unobservable inputs:
	Intangible Asset	Valuation Date	Fair Value	Valuation Technique	Unobservable Input	Rate
	In-Process R&D	31-Mar-14	$6 million	Income Approach - Excess Earnings Method	Discount Rate	20%
	Core Technology	31-Mar-14	$64 million	Income Approach - Excess Earnings Method	Discount Rate	15%

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Gains (losses) recognized in earnings for derivatives designed as hedging instruments	'
	The following presents the effect of our derivative instruments designated as cash flow hedges under Topic 815 on our accompanying unaudited condensed consolidated statements of operations during the first quarter of 2014 and 2013 (in millions):
		Amount of Pre-tax				Amount of Pre-tax Gain (Loss) Reclassified from AOCI into Earnings				Location in Statement of
		Gain (Loss)				(Effective Portion)				Operations
		Recognized in OCI
		(Effective Portion)
	Three Months Ended March 31, 2014
	Currency hedge contracts	(21		)		21				Cost of products sold
		$	(21	)		$	21
	Three Months Ended March 31, 2013
	Currency hedge contracts	$	113			$	(6	)		Cost of products sold
		$	113			$	(6	)
Gains (losses) recognized in earnings for derivatives not designated as hedging instruments	'
	The amount of gain (loss) recognized in earnings related to the ineffective portion of hedging relationships was de minimis for all periods presented.
Net foreign currency gain (loss) [Table Text Block]	'
	Net gains and losses on currency hedge contracts not designated as hedging instruments were offset by net losses and gains from foreign currency transaction exposures, as shown in the following table:
	in millions				Three Months Ended
			Location in Statement of Operations		March 31,
					2014				2013
	Gain (loss) on currency hedge contracts		Other, net		$	21			$	26
	Gain (loss) on foreign currency transaction exposures		Other, net		(24		)		(28		)
	Net foreign currency gain (loss)		Other, net		$	(3	)		$	(2	)
Classification of derivative assets and liabilities within level 2	'
	The following are the balances of our derivative assets and liabilities as of March 31, 2014 and December 31, 2013:
			As of
			March 31,				December 31,
	(in millions)	Location in Balance Sheet (1)	2014				2013
	Derivative Assets:
	Designated Hedging Instruments
	Currency hedge contracts	Prepaid and other current assets	$	106			$	117
	Currency hedge contracts	Other long-term assets	88				120
	Interest rate contracts	Prepaid and other current assets	4				1
	Interest rate contracts	Other long-term assets	2				—
			200				238
	Non-Designated Hedging Instruments
	Currency hedge contracts	Prepaid and other current assets	21				27
	Total Derivative Assets		$	221			$	265
	Derivative Liabilities:
	Designated Hedging Instruments
	Currency hedge contracts	Other current liabilities	$	13			$	13
	Currency hedge contracts	Other long-term liabilities	19				19
	Interest rate contracts	Other long-term liabilities	—				8
			32				40
	Non-Designated Hedging Instruments
	Currency hedge contracts	Other current liabilities	24				23
	Total Derivative Liabilities		$	56			$	63
	-1	We classify derivative assets and liabilities as current when the remaining term of the derivative contract is one year or less.
Assets and liabilities measured at fair value on a recurring basis	'
	Assets and liabilities measured at fair value on a recurring basis consist of the following as of March 31, 2014 and December 31, 2013:
		As of March 31, 2014												As of December 31, 2013
	(in millions)	Level 1				Level 2				Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets
	Money market and government funds	$	29			$	—			$	—	$	29	$	38	$	—	$	—	$	38
	Currency hedge contracts	—				215				—		215		—		264		—		264
	Interest rate contracts	—				6				—		6		—		1		—		1
		$	29			$	221			$	—	$	250	$	38	$	265	$	—	$	303
	Liabilities
	Currency hedge contracts	$	—			$	56			$	—	$	56	$	—	$	55	$	—	$	55
	Accrued contingent consideration	—				—				472		472		—		—		501		501
	Interest rate contracts	—				—				—		—		—		8		—		8
		$	—			$	56			$	472	$	528	$	—	$	63	$	501	$	564

Borrowings_and_Credit_Arrangem1

Borrowings and Credit Arrangements (Tables)	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Schedule of debt maturities	'
	The debt maturity schedule for the significant components of our debt obligations as of March 31, 2014 is as follows:
	(in millions)	2014			2015		2016		2017		2018		Thereafter		Total
	Senior notes	$	—		$	400	$	600	$	250	$	600	$	1,950	$	3,800
	Term loan	—			—		80		80		240		—		400
		$	—		$	400	$	680	$	330	$	840	$	1,950	$	4,200
		Note:	The table above does not include unamortized discounts associated with our senior notes, or amounts related to interest rate contracts used to hedge the fair value of certain of our senior notes.
Summary of revolving credit facility agreement compliance with debt covenants	'
	Our revolving credit facility agreement in place as of March 31, 2014 requires that we maintain certain financial covenants, as follows:
		Covenant		Actual as of
		Requirement		31-Mar-14
	Maximum leverage ratio (1)	3.5 times		2.4 times
	Minimum interest coverage ratio (2)	3.0 times		5.6 times
	-1	Ratio of total debt to consolidated EBITDA, as defined by the credit agreement, for the preceding four consecutive fiscal quarters.
	-2	Ratio of consolidated EBITDA, as defined by the credit agreement, to interest expense for the preceding four consecutive fiscal quarters.

Restructuring_Related_Activiti1

Restructuring Related Activities (Tables)	3 Months Ended
	Mar. 31, 2014
Restructuring and Related Cost [Line Items]	'
Restructuring and related costs	'
	The following presents these costs (credits) by major type and line item within our accompanying unaudited condensed consolidated statements of operations, as well as by program:
	Three Months Ended March 31, 2014
	(in millions)	Termination				Accelerated				Transfer				Fixed Asset			Other		Total
		Benefits				Depreciation				Costs				Write-offs
	Restructuring charges	$	11			$	—			$	—			$	—		$	9	$	20
	Restructuring-related expenses:
	Cost of products sold	—				—				2				—			—		2
	Selling, general and administrative expenses	—				1				—				—			5		6
		—				1				2				—			5		8
		$	11			$	1			$	2			$	—		$	14	$	28
	(in millions)	Termination				Accelerated				Transfer				Fixed Asset			Other		Total
		Benefits				Depreciation				Costs				Write-offs
	2014 Restructuring plan	$	9			$	1			$	2			$	—		$	11	$	23
	2011 Restructuring plan (including the Expansion)	2				—				—				—			3		5
		$	11			$	1			$	2			$	—		$	14	$	28
	Three Months Ended March 31, 2013
	(in millions)	Termination				Accelerated				Transfer				Net Gain on Fixed Asset Disposals			Other		Total
		Benefits				Depreciation				Costs
	Restructuring charges	$	8			$	—			$	—			$	(17	)	$	19	$	10
	Restructuring-related expenses:
	Cost of products sold	—				—				—				—			—		—
	Selling, general and administrative expenses	—				1				—				—			4		5
		—				1				—				—			4		5
		$	8			$	1			$	—			$	(17	)	$	23	$	15
	(in millions)	Termination				Accelerated				Transfer				Net Gain on Fixed Asset Disposals			Other		Total
		Benefits				Depreciation				Costs
	2011 Restructuring plan (including the Expansion)	$	10			$	1			$	—			$	(17	)	$	23	$	17
	Plant Network Optimization program	(2		)		—				—				—			—		(2		)
		$	8			$	1			$	—			$	(17	)	$	23	$	15
Cumulative restructuring charges	'
	The following presents these costs by major type and by plan:
	(in millions)	2014				2011				Plant				Total
		Restructuring				Restructuring				Network
		plan				plan (including the Expansion)				Optimization program
	Termination benefits	$	37			$	138			$	30			$	205
	Fixed asset write-offs	—				(1		)		—				(1		)
	Other	7				113				—				120
	Total restructuring charges	44				250				30				324
	Accelerated depreciation	1				5				22				28
	Transfer costs	2				—				74				76
	Other	6				34				—				40
	Restructuring-related expenses	9				39				96				144
		$	53			$	289			$	126			$	468
Cash payments associated with restructuring initiatives	'
	ayments were made using cash generated from operations, and are comprised of the following:
	(in millions)	2014				2011				Plant				Total
		Restructuring				Restructuring				Network
		plan				plan (including the Expansion)				Optimization program
	Three Months Ended March 31, 2014
	Termination benefits	$	6			$	7			$	—			$	13
	Transfer costs	2				—				—				2
	Other	9				5				—				14
		$	17			$	12			$	—			$	29
	Program to Date
	Termination benefits	$	6			$	131			$	30			$	167
	Transfer costs	2				—				73				75
	Other	9				149				—				158
		$	17			$	280			$	103			$	400
Summary of accrued expenses within accompanying unaudited condensed consolidated balance sheets	'
	The following is a rollforward of the termination benefit liability associated with our 2014 Restructuring plan and 2011 Restructuring plan (including the Expansion), which is reported as a component of accrued expenses included in our accompanying unaudited condensed balance sheets:
	(in millions)		2014				2011				Total
			Restructuring				Restructuring
			plan				plan (including the Expansion)
	Accrued as of December 31, 2013		$	29			$	12			$	41
	Charges (credits)		9				2				11
	Cash payments		(6		)		(7		)		(13		)
	Other adjustments		—				—				—
	Accrued as of March 31, 2014		$	32			$	7			$	39
2014 Restructuring plan [Member]	'
Restructuring and Related Cost [Line Items]	'
Restructuring and related costs	'
	The following table provides a summary of our estimates of costs associated with the 2014 Restructuring plan by major type of cost:
	Type of cost	Total estimated amount expected to
		be incurred
	Restructuring charges:
	Termination benefits	$100 million to $120 million
	Other (1)	$5 million to $15 million
	Restructuring-related expenses:
	Other (2)	$70 million to $90 million
		$175 million to $225 million
	(1) Consists primarily of consultant fees and costs associated with contractual cancellations.
	(2) Comprised of other costs directly related to the 2014 Restructuring plan, including program management, accelerated depreciation, and costs to transfer product lines among facilities.
2011 Restructuring Plan [Member]	'
Restructuring and Related Cost [Line Items]	'
Restructuring and related costs	'
	The following provides a summary of our expected total costs associated with the 2011 Restructuring plan, including the Expansion, by major type of cost:
	Type of cost	Total estimated amount expected to
		be incurred
	Restructuring charges:
	Termination benefits	$137 million to $140 million
	Other (1)	$114 million
	Restructuring-related expenses:
	Other (2)	$38 million
		$289 million to $292 million
	-1	Includes primarily consulting fees, gains and losses on disposals of fixed assets and costs associated with contractual cancellations.
	-2	Comprised of other costs directly related to the 2011 Restructuring plan, including the Expansion, such as program management, accelerated depreciation, retention and infrastructure-related costs.
Plant Network Optimization [Member]	'
Restructuring and Related Cost [Line Items]	'
Restructuring and related costs	'
	The following provides a summary of our costs associated with the Plant Network Optimization program by major type of cost:
	Type of cost	Total amount incurred
	Restructuring charges:
	Termination benefits	$30 million
	Restructuring-related expenses:
	Accelerated depreciation	$22 million
	Transfer costs (1)	$74 million
		$126 million
	-1	Consists primarily of costs to transfer product lines among facilities, including costs of transfer teams, freight, idle facility and product line validations.

Supplemental_Balance_Sheet_Inf1

Supplemental Balance Sheet Information (Tables)	3 Months Ended
	Mar. 31, 2014
Supplemental Balance Sheet Information [Abstract]	'
Trade accounts receivable, net	'
		As of
	(in millions)	31-Mar-14			31-Dec-13
	Accounts receivable	$	1,322		$	1,419
	Less: allowance for doubtful accounts	(75		)	(81		)
	Less: allowance for sales returns	(30		)	(31		)
		$	1,217		$	1,307
Rollforward of allowances for doubtful accounts	'
		Three Months Ended
		March 31,
	(in millions)	2014			2013
	Beginning balance	$	81		$	88
	Charges to expenses	(2		)	3
	Utilization of allowances	(4		)	(5		)
	Ending balance	$	75		$	86
Inventory Disclosure [Text Block]	'
		As of
	(in millions)	31-Mar-14			31-Dec-13
	Finished goods	$	611		$	598
	Work-in-process	116			90
	Raw materials	199			209
		$	926		$	897
Property, plant and equipment, net	'
		As of
	(in millions)	31-Mar-14			31-Dec-13
	Land	$	81		$	81
	Buildings and improvements	919			917
	Equipment, furniture and fixtures	2,492			2,461
	Capital in progress	234			211
		3,726			3,670
	Less: accumulated depreciation	2,187			2,124
		$	1,539		$	1,546
Schedule of Accrued Liabilities	'
		As of
	(in millions)	31-Mar-14			31-Dec-13
	Payroll and related liabilities	$	370		$	488
	Accrued contingent consideration	228			148
	Legal reserves	98			84
	Other	579			628
		$	1,275		$	1,348
Other long-term liabilities	'
		As of
	(in millions)	31-Mar-14			31-Dec-13
	Accrued income taxes	$	1,231		$	1,283
	Accrued contingent consideration	244			353
	Legal reserves	498			523
	Other long-term liabilities	425			410
		$	2,398		$	2,569
Accrued warranties	'
		Three Months Ended
		March 31,
		2014			2013
	Beginning Balance	$	28		$	26
	Provision	4			4
	Settlements/reversals	(3		)	(3		)
	Ending Balance	$	29		$	27

Weighted_Average_Shares_Outsta1

Weighted Average Shares Outstanding (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Schedule of Weighted Average Number of Shares [Table Text Block]	'
		Three Months Ended
		March 31,
	(in millions)	2014	2013
	Weighted average shares outstanding - basic	1,321.70	1,351.90
	Net effect of common stock equivalents	27.5	—	*
	Weighted average shares outstanding - assuming dilution	1,349.20	1,351.90
	* We generated a net loss in the first quarter of 2013. Our weighted-average shares outstanding for earnings per share calculations
	exclude common stock equivalents of 12.8 million for the first quarter of 2013 due to our net loss position in this period.

Segment_Reporting_Tables

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment Reporting Information By Segment	'
	A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying unaudited condensed consolidated statements of operations is as follows:
		Three Months Ended
		March 31,
	(in millions)	2014			2013
					(restated)
	Net sales
	Interventional Cardiology	$	501		$	498
	Peripheral Interventions	204			193
	Cardiovascular	705			691
	Cardiac Rhythm Management	464			475
	Electrophysiology	58			34
	Rhythm Management	522			509
	Endoscopy	316			300
	Urology and Women's Health	126			117
	Neuromodulation	109			89
	MedSurg	551			506
	Net sales allocated to reportable segments	1,778			1,706
	Sales generated from divested businesses	2			36
	Impact of foreign currency fluctuations	(6		)	19
		$	1,774		$	1,761
	Income (loss) before income taxes
	Cardiovascular	$	171		$	158
	Rhythm Management	66			57
	MedSurg	168			140
	Operating income allocated to reportable segments	405			355
	Corporate expenses and currency exchange	(50		)	(42		)
	Goodwill and other intangible asset impairment charges; and acquisition-, divestiture-, restructuring-, and litigation related charges or credits	(49		)	(540		)
	Amortization expense	(109		)	(103		)
	Operating income (loss)	197			(330		)
	Other expense, net	(51		)	(64		)
	Income (loss) before income taxes	$	146		$	(394	)

Changes_in_Other_Comprehensive1

Changes in Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2014
Changes in Other Comprehensive Income [Abstract]	'
Changes in Other Comprehensive Income [Table Text Block]	'
	The following table provides the reclassifications out of other comprehensive income for the three months ended March 31, 2014 and March 31, 2013. Amounts in the chart below are presented net of tax.
	Three Months Ended March 31, 2014
	(in millions)	Foreign currency translation adjustments	Unrealized gains/losses on derivative financial instruments	Defined benefit pension items / Other	Total
	Balance as of December 31, 2013	($16)	$141	($19)	$106
	Other comprehensive income (loss) before reclassifications	-6	-14	-1	-21
	Amounts reclassified from accumulated other comprehensive income	—	-13	—	-13
	Net current-period other comprehensive income	-6	-27	-1	-34
	Balance as of March 31, 2014	($22)	$114	($20)	$72
	Three Months Ended March 31, 2013
	(in millions)	Foreign currency translation adjustments	Unrealized gains/losses on derivative financial instruments	Defined benefit pension items / Other	Total
	Balance as of December 31, 2012	($26)	$34	($41)	($33)
	Other comprehensive income (loss) before reclassifications	3	71	—	74
	Amounts reclassified from accumulated other comprehensive income	—	4	—	4
	Net current-period other comprehensive income	3	75	—	78
	Balance as of March 31, 2013	($23)	$109	($41)	$45

Acquisitions_Details

Acquisitions (Details) (USD $)

3 Months Ended

3 Months Ended

0 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

7-May-14

R&D- and commercialization-based milestones [Member]

R&D- and commercialization-based milestones [Member]

R&D- and commercialization-based milestones [Member]

revenue-based payments [Member]

revenue-based payments [Member]

revenue-based payments [Member]

revenue-based payments [Member]

revenue-based payments [Member]

revenue-based payments [Member]

IoGyn [Member]

Subsequent Event [Member]

Minimum [Member]

Maximum [Member]

Discounted cash flow [Member]

Discounted cash flow [Member]

Discounted cash flow [Member]

Monte Carlo [Member]

Monte Carlo [Member]

Monte Carlo [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued Contingent Consideration

($472,000,000)

'

($501,000,000)

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Liabilities Arising from Contingencies, Amount Recognized

-3,000,000

0

'

'

'

'

'

'

'

'

'

'

'

'

Adjustments to accrued contingent consideration

-2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Benefit related to change in fair value of contingent liability

22,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent payment related to business combination

12,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum future contingent consideration for acquisitions

2,200,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Contingent Consideration, Liability

'

'

'

-87,000,000

'

'

-131,000,000

'

'

-254,000,000

'

'

'

'

Revenue Volatility - Contingent Consideration

'

'

'

'

'

'

'

'

'

13.00%

'

'

'

'

contingent consideration liability, projected year of payment

'

'

'

'

'2014

'2015

'

'2014

'2018

'

'2014

'2018

'

'

contingent consideration liability, probability of payment

'

'

'

'

85.00%

95.00%

'

0.00%

100.00%

19.00%

'

'

'

'

Risk-adjusted discount rate for contingent consideration

'

'

'

'

0.70%

1.40%

'

11.50%

15.00%

'

'

'

'

'

Minority interest owned of IoGyn

28.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Accounts and Notes Receivable, Net

'

'

'

'

'

'

'

'

'

'

'

'

8,000,000

'

Payments to Acquire Businesses, Net of Cash Acquired

$8,000,000

$0

'

'

'

'

'

'

'

'

'

'

'

$65,000,000

Remaining equity of IoGyn purchased

'

'

'

'

'

'

'

'

'

'

'

'

'

72.00%

Divestitures_Details

Divestitures (Details) (USD $)	1 Months Ended	3 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2011	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Divestitures and Assets Held for Sale [Abstract]	'	'	'	'	'	'
Purchase price for divestiture of business/controlling interest	$1,500	'	'	'	'	'
Proceeds from business divestitures, net of costs	'	12	0	28	10	1,450
Proceeds from divestiture of business, excluding amounts placed in escrow	1,426	'	'	'	'	'
Amount Placed In Escrow Included In Proceeds From Divestiture Of Business	24	'	'	'	'	'
Revenues generated by the Neurovascular business	'	$2	$36	'	'	'

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
	reportablesegments
Goodwill [Line Items]	'	'	'
Research and Development in Process	$6,000,000	'	'
Asset Impairment Charges	55,000,000	'	'
Finite-Lived Intangible Assets, Gross	9,599,000,000	'	9,630,000,000
Finite-Lived Intangible Assets, Accumulated Amortization	-4,256,000,000	'	-4,147,000,000
Indefinite-lived intangible assets, including goodwill	15,794,000,000	'	15,790,000,000
Indefinite-lived intangible assets, accumulated write-offs	-9,900,000,000	'	-9,900,000,000
Goodwill	5,697,000,000	'	5,693,000,000
Goodwill, Purchase Accounting Adjustments	-2,000,000	'	'
Goodwill, Acquired During Period	6,000,000	'	'
Goodwill, Impaired, Accumulated Impairment Loss	-9,900,000,000	'	-9,900,000,000
Goodwill (Textuals) [Abstract]	'	'	'
Number of Reportable Segments	3	'	'
Goodwill impairment charge	0	-423,000,000	'
Goodwill, Impairment Loss, Net of Tax	'	-422,000,000	'
Goodwill, Other Changes	0	'	'
Core technology	64,000,000	'	'
Global CRM Reporting Unit [Member]	'	'	'
Goodwill [Line Items]	'	'	'
Finite-Lived Intangible Assets, Net	4,305,000,000	'	'
Cardiovascular [Member]	'	'	'
Goodwill [Line Items]	'	'	'
Goodwill	3,259,000,000	'	3,252,000,000
Goodwill, Purchase Accounting Adjustments	0	'	'
Goodwill, Acquired During Period	0	'	'
Goodwill, Impaired, Accumulated Impairment Loss	-1,479,000,000	'	-1,479,000,000
Goodwill (Textuals) [Abstract]	'	'	'
Goodwill impairment charge	0	'	'
Goodwill, Other Changes	7,000,000	'	'
Rhythm Management [Member]	'	'	'
Goodwill [Line Items]	'	'	'
Goodwill	292,000,000	'	294,000,000
Goodwill, Purchase Accounting Adjustments	-2,000,000	'	'
Goodwill, Acquired During Period	0	'	'
Goodwill, Impaired, Accumulated Impairment Loss	-6,960,000,000	'	-6,960,000,000
Goodwill (Textuals) [Abstract]	'	'	'
Goodwill impairment charge	0	'	'
Goodwill, Other Changes	0	'	'
MedSurg [Member]	'	'	'
Goodwill [Line Items]	'	'	'
Goodwill	2,146,000,000	'	2,147,000,000
Goodwill, Purchase Accounting Adjustments	0	'	'
Goodwill, Acquired During Period	6,000,000	'	'
Goodwill, Impaired, Accumulated Impairment Loss	-1,461,000,000	'	-1,461,000,000
Goodwill (Textuals) [Abstract]	'	'	'
Goodwill impairment charge	0	'	'
Goodwill, Other Changes	-7,000,000	'	'
Unclassified Indefinite-lived Intangible Assets [Member]	'	'	'
Goodwill [Line Items]	'	'	'
Goodwill, Gross	15,597,000,000	'	15,593,000,000
Goodwill, Impaired, Accumulated Impairment Loss	-9,900,000,000	'	-9,900,000,000
Technology-related [Member]	'	'	'
Goodwill [Line Items]	'	'	'
Indefinite-Lived Intangible Assets (Excluding Goodwill)	197,000,000	'	197,000,000
In-process research and development [Member]	'	'	'
Goodwill [Line Items]	'	'	'
Indefinite-Lived Intangible Assets (Excluding Goodwill)	262,000,000	'	270,000,000
Technology-related [Member]	'	'	'
Goodwill [Line Items]	'	'	'
Finite-Lived Intangible Assets, Gross	8,232,000,000	'	8,272,000,000
Finite-Lived Intangible Assets, Accumulated Amortization	-3,431,000,000	'	-3,342,000,000
Patents [Member]	'	'	'
Goodwill [Line Items]	'	'	'
Finite-Lived Intangible Assets, Gross	521,000,000	'	513,000,000
Finite-Lived Intangible Assets, Accumulated Amortization	-332,000,000	'	-326,000,000
Other Intangible Assets [Member]	'	'	'
Goodwill [Line Items]	'	'	'
Finite-Lived Intangible Assets, Gross	846,000,000	'	845,000,000
Finite-Lived Intangible Assets, Accumulated Amortization	($493,000,000)	'	($479,000,000)
In Process Research and Development [Member]	'	'	'
Goodwill (Textuals) [Abstract]	'	'	'
Fair Value Inputs, Discount Rate	20.00%	'	'
Core technology [Member]	'	'	'
Goodwill (Textuals) [Abstract]	'	'	'
Fair Value Inputs, Discount Rate	15.00%	'	'

Fair_Value_Measurements_Fair_V

Fair Value Measurements Fair Value Measurements (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Derivative, Notional Amount	$2,736	'	$2,564
Foreign Currency Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net	21	-6	'
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	69	'	'
Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax, Ending Balance	112	'	139
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments at Fair Value, Net	2,157	'	1,952
Interest Rate Derivatives, at Fair Value, Net	450	'	'
Gain/Loss related to ineffective portion of hedging relationships	10	'	'
Unamortized gains on senior notes	52	'	54
Unamortized losses on senior notes	2	'	2
Unrealized gain on interest rate cash flow hedges, pretax, AOCI	3	'	3
reduction of interest expense, related to amortization of previously terminated interest rate contracts	2	'	'
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net	9	'	'
Derivative Assets	221	'	265
Derivative Liabilities	56	'	63
Interest Rate Derivative Assets, at Fair Value	6	'	1
Accrued Contingent Consideration	472	'	501
Interest Rate Derivative Liabilities, at Fair Value	0	'	8
Time Deposits, at Carrying Value	9	'	31
Cash	153	'	148
Cost-method Investments, Aggregate Carrying Amount	26	'	20
Asset Impairment Charges	55	'	'
Goodwill and intangible asset impairment losses in period	'	423	'
Debt Instrument, Fair Value Disclosure	4,662	'	4,602
Loss on hedged debt obligation [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Interest Expense, Other	10	'	'
Fair Value, Inputs, Level 1 [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Interest Rate Derivative Assets, at Fair Value	0	'	0
Interest Rate Derivative Liabilities, at Fair Value	0	'	0
Fair Value, Inputs, Level 2 [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Money Market Funds, at Carrying Value	0	'	'
Interest Rate Derivative Assets, at Fair Value	6	'	1
Interest Rate Derivative Liabilities, at Fair Value	0	'	8
Fair Value, Inputs, Level 3 [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Interest Rate Derivative Assets, at Fair Value	0	'	0
Interest Rate Derivative Liabilities, at Fair Value	0	'	0
Fair Value, Measurements, Recurring [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Money Market Funds, at Carrying Value	29	'	38
Foreign Currency Contract, Asset, Fair Value Disclosure	215	'	264
Assets, Fair Value Disclosure	250	'	303
Foreign Currency Contracts, Liability, Fair Value Disclosure	56	'	55
Accrued Contingent Consideration	472	'	501
Liabilities, Fair Value Disclosure	528	'	564
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Money Market Funds, at Carrying Value	29	'	38
Foreign Currency Contract, Asset, Fair Value Disclosure	0	'	0
Assets, Fair Value Disclosure	29	'	38
Foreign Currency Contracts, Liability, Fair Value Disclosure	0	'	0
Accrued Contingent Consideration	0	'	0
Liabilities, Fair Value Disclosure	0	'	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Money Market Funds, at Carrying Value	'	'	0
Foreign Currency Contract, Asset, Fair Value Disclosure	215	'	264
Assets, Fair Value Disclosure	221	'	265
Foreign Currency Contracts, Liability, Fair Value Disclosure	56	'	55
Accrued Contingent Consideration	0	'	0
Liabilities, Fair Value Disclosure	56	'	63
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Money Market Funds, at Carrying Value	0	'	0
Foreign Currency Contract, Asset, Fair Value Disclosure	0	'	0
Assets, Fair Value Disclosure	0	'	0
Foreign Currency Contracts, Liability, Fair Value Disclosure	0	'	0
Accrued Contingent Consideration	472	'	501
Liabilities, Fair Value Disclosure	472	'	501
Interest Rate Swap [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Derivative, Notional Amount	'	'	450
Designated as Hedging Instrument [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Derivative Instruments in Hedges, Assets, at Fair Value	200	'	238
Derivative Instruments in Hedges, Liabilities, at Fair Value	32	'	40
Designated as Hedging Instrument [Member] | Prepaid And Other Current Assets [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Derivative Instruments in Hedges, Assets, at Fair Value	106	'	117
Designated as Hedging Instrument [Member] | Other Long Term Assets [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Derivative Instruments in Hedges, Assets, at Fair Value	88	'	120
Designated as Hedging Instrument [Member] | Other current liabilities [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Derivative Instruments in Hedges, Liabilities, at Fair Value	13	'	13
Designated as Hedging Instrument [Member] | Other Long Term Liabilities [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Derivative Instruments in Hedges, Liabilities, at Fair Value	19	'	19
Not Designated as Hedging Instrument [Member] | Prepaid And Other Current Assets [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value	21	'	27
Not Designated as Hedging Instrument [Member] | Other current liabilities [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value	24	'	23
Not Designated as Hedging Instrument [Member] | Other, net [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net	21	26	'
Net gain (loss) from foreign currency transaction exposures	-24	-28	'
Foreign Currency Transaction Gain (Loss), Realized	-3	-2	'
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	-21	113	'
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	21	-6	'
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Cost of products sold [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	-21	113	'
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	21	-6	'
Interest Rate Contract [Member] | Designated as Hedging Instrument [Member] | Prepaid And Other Current Assets [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Derivative Instruments in Hedges, Assets, at Fair Value	4	'	1
Interest Rate Contract [Member] | Designated as Hedging Instrument [Member] | Other Long Term Assets [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Derivative Instruments in Hedges, Assets, at Fair Value	2	'	0
Interest Rate Contract [Member] | Designated as Hedging Instrument [Member] | Other Long Term Liabilities [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Derivative Instruments in Hedges, Liabilities, at Fair Value	$0	'	$8

Borrowings_and_Credit_Arrangem2

Borrowings and Credit Arrangements (Details)

3 Months Ended

12 Months Ended

3 Months Ended

In Millions, unless otherwise specified

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Apr. 18, 2012

Mar. 31, 2014

Aug. 06, 2013

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

USD ($)

USD ($)

Uncommitted Credit Facilities With A Commercial Japanese Banks [Member]

Uncommitted Credit Facilities With A Commercial Japanese Banks [Member]

Uncommitted Credit Facilities With A Commercial Japanese Banks [Member]

Italy, Spain, Portugal and Greece [Member]

Covenant Requirement [Member]

Actual, Covenant [Member]

Revolving credit facility [Member]

Revolving credit facility [Member]

Unsecured Term Loan Facility [Member]

Unsecured Term Loan Facility [Member]

Senior Notes [Member]

Unsecured Term Loan Facility [Member]

Unsecured Term Loan Facility [Member]

USD ($)

JPY (¥)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Schedule of debt maturities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term Debt, Maturities, Repayments of Principal in Current Year

$0

'

'

'

'

'

'

'

'

'

'

'

$0

$0

'

Long-term Debt, Maturities, Repayments of Principal in Year Two

400

'

'

'

'

'

'

'

'

'

'

'

400

0

'

Long-term Debt, Maturities, Repayments of Principal in Year Three

680

'

'

'

'

'

'

'

'

'

'

'

600

80

'

Long-term Debt, Maturities, Repayments of Principal in Year Four

330

'

'

'

'

'

'

'

'

'

'

'

250

80

'

Long-term Debt, Maturities, Repayments of Principal in Year Five

840

'

'

'

'

'

'

'

'

'

'

'

600

240

'

Long-term Debt, Maturities, Repayments of Principal After Year Five

1,950

'

'

'

'

'

'

'

'

'

'

'

1,950

0

'

Long-term Debt, Maturities, Total Repayments of Principal

4,200

'

'

'

'

'

'

'

'

'

'

'

3,800

400

400

Summary of compliance with debt covenants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum Leverage Ratio

'

'

'

'

'

'

3.5

2.4

'

'

'

'

'

'

'

Minimum interest coverage ratio

'

'

'

'

'

'

3

5.6

'

'

'

'

'

'

'

Borrowings and Credit Arrangements (Textuals) [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total debt

4,249

4,240

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity

300

'

'

'

'

'

'

'

'

2,000

'

'

'

'

'

Interest Margin above LIBOR, Minimum

'

'

'

'

'

'

'

'

'

0.88%

'

1.00%

'

'

'

Interest Margin above LIBOR, Maximum

'

'

'

'

'

'

'

'

'

1.48%

'

1.75%

'

'

'

Line of Credit Facility, Current Interest Rate

'

'

'

'

'

'

'

'

1.28%

'

'

'

'

'

'

Commitment fee percentage

'

'

'

'

'

'

'

'

0.23%

'

'

'

'

'

'

Exclusion from EBITDA for Restructuring Charges

'

'

'

'

'

'

'

'

'

500

'

'

'

'

'

Restructuring charges remaining to be excluded from calculation of consolidated EBITDA

'

'

'

'

'

'

'

'

206

'

'

'

'

'

'

Litigation and Debt Exclusion from EBITDA

'

'

'

'

'

'

'

'

'

2,300

'

'

'

'

'

Legal payments and debt remaining to be excluded from calculation of consolidated EBITDA

'

'

'

'

'

'

'

'

2,183

'

'

'

'

'

'

Unsecured Term Loan Facility, Interest Rate During Period

'

'

'

'

'

'

'

'

'

'

1.50%

'

'

'

'

Quarterly term-loan principal payments

'

'

'

'

'

'

'

'

'

'

20

'

'

'

'

Senior notes

3,800

3,800

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum amount of proceeds from sale of finance receivables

312

'

203

21,000

'

'

'

'

'

'

'

'

'

'

'

Average interest rate of de-recognized receivables

3.60%

3.30%

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash receipts on long outstanding Spain receivables

80

'

'

'

'

'

'

'

'

'

'

'

'

'

'

De-recognized receivables

158

146

144

'

147

'

'

'

'

'

'

'

'

'

'

Accounts receivable 180 days past due

'

'

'

'

'

36

'

'

'

'

'

'

'

'

'

Accounts receivable 360 days past due

'

'

'

'

'

17

'

'

'

'

'

'

'

'

'

Average discounted rates of notes receivables

'

'

1.50%

1.50%

1.80%

'

'

'

'

'

'

'

'

'

'

Letters of Credit Outstanding, Amount

$78

$78

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring_Related_Activiti2

Restructuring Related Activities (Details) (USD $)

3 Months Ended

62 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

32 Months Ended

3 Months Ended

62 Months Ended

3 Months Ended

62 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

32 Months Ended

3 Months Ended

62 Months Ended

3 Months Ended

62 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

32 Months Ended

3 Months Ended

62 Months Ended

3 Months Ended

62 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

32 Months Ended

3 Months Ended

62 Months Ended

3 Months Ended

62 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

32 Months Ended

3 Months Ended

62 Months Ended

3 Months Ended

62 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

32 Months Ended

3 Months Ended

62 Months Ended

3 Months Ended

In Millions, unless otherwise specified

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

2014 Restructuring plan [Member]

2014 Restructuring plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

Plant Network Optimization [Member]

Plant Network Optimization [Member]

Plant Network Optimization [Member]

Termination Benefits [Member]

Termination Benefits [Member]

Termination Benefits [Member]

Termination Benefits [Member]

Termination Benefits [Member]

Termination Benefits [Member]

Termination Benefits [Member]

Termination Benefits [Member]

Termination Benefits [Member]

Termination Benefits [Member]

Termination Benefits [Member]

Termination Benefits [Member]

Termination Benefits [Member]

Termination Benefits [Member]

Accelerated depreciation [Member]

Accelerated depreciation [Member]

Accelerated depreciation [Member]

Accelerated depreciation [Member]

Accelerated depreciation [Member]

Accelerated depreciation [Member]

Accelerated depreciation [Member]

Accelerated depreciation [Member]

Accelerated depreciation [Member]

Accelerated depreciation [Member]

Transfer costs [Member]

Transfer costs [Member]

Transfer costs [Member]

Transfer costs [Member]

Transfer costs [Member]

Transfer costs [Member]

Transfer costs [Member]

Transfer costs [Member]

Transfer costs [Member]

Transfer costs [Member]

Transfer costs [Member]

Impairment of an asset in value [Member]

Impairment of an asset in value [Member]

Impairment of an asset in value [Member]

Impairment of an asset in value [Member]

Impairment of an asset in value [Member]

Impairment of an asset in value [Member]

Impairment of an asset in value [Member]

Impairment of an asset in value [Member]

Impairment of an asset in value [Member]

Impairment of an asset in value [Member]

Other [Member]

Other [Member]

Other [Member]

Other [Member]

Other [Member]

Other [Member]

Other [Member]

Other [Member]

Other [Member]

Other [Member]

Other [Member]

Other [Member]

Restructuring Plan [Member]

Restructuring Plan [Member]

Restructuring Related To Plan [Member]

Restructuring Related To Plan [Member]

Restructuring Related To Plan [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Cost of products sold [Member]

Cost of products sold [Member]

Cost of products sold [Member]

Cost of products sold [Member]

Cost of products sold [Member]

Cost of products sold [Member]

Cost of products sold [Member]

Cost of products sold [Member]

Cost of products sold [Member]

Cost of products sold [Member]

Cost of products sold [Member]

Cost of products sold [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

2014 Restructuring plan [Member]

2014 Restructuring plan [Member]

2014 Restructuring plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

Plant Network Optimization [Member]

Plant Network Optimization [Member]

Plant Network Optimization [Member]

2014 Restructuring plan [Member]

2014 Restructuring plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

Plant Network Optimization [Member]

Plant Network Optimization [Member]

2014 Restructuring plan [Member]

2014 Restructuring plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

Plant Network Optimization [Member]

Plant Network Optimization [Member]

Plant Network Optimization [Member]

2014 Restructuring plan [Member]

2014 Restructuring plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

Plant Network Optimization [Member]

Plant Network Optimization [Member]

2014 Restructuring plan [Member]

2014 Restructuring plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

Plant Network Optimization [Member]

Plant Network Optimization [Member]

Plant Network Optimization [Member]

Termination Benefits [Member]

Other [Member]

Accelerated depreciation [Member]

Transfer costs [Member]

Other [Member]

2014 Restructuring plan [Member]

2011 Restructuring Plan [Member]

Restructuring Plan [Member]

Restructuring Plan [Member]

Restructuring Plan [Member]

Restructuring Related To Plan [Member]

2014 Restructuring plan [Member]

2011 Restructuring Plan [Member]

Restructuring Plan [Member]

Restructuring Plan [Member]

Restructuring Plan [Member]

Restructuring Related To Plan [Member]

Termination Benefits [Member]

Termination Benefits [Member]

Accelerated depreciation [Member]

Accelerated depreciation [Member]

Transfer costs [Member]

Transfer costs [Member]

Impairment of an asset in value [Member]

Impairment of an asset in value [Member]

Other [Member]

Other [Member]

Termination Benefits [Member]

Termination Benefits [Member]

Accelerated depreciation [Member]

Accelerated depreciation [Member]

Transfer costs [Member]

Transfer costs [Member]

Impairment of an asset in value [Member]

Impairment of an asset in value [Member]

Other [Member]

Other [Member]

Plant Network Optimization [Member]

2011 Restructuring Plan [Member]

Plant Network Optimization [Member]

Plant Network Optimization [Member]

2011 Restructuring Plan [Member]

Termination Benefits [Member]

Termination Benefits [Member]

Other [Member]

Other [Member]

Termination Benefits [Member]

Termination Benefits [Member]

Other [Member]

Other [Member]

2014 Restructuring plan [Member]

2011 Restructuring Plan [Member]

2014 Restructuring plan [Member]

2014 Restructuring plan [Member]

2014 Restructuring plan [Member]

2011 Restructuring Plan [Member]

2014 Restructuring plan [Member]

2014 Restructuring plan [Member]

Restructuring and Related Cost [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring Reserve

'

'

'

'

'

'

'

'

'

'

'

$39

'

$39

$41

$32

$32

$29

$7

'

$7

$12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8

'

$8

$8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring Charges Incurred to Date

'

'

324

'

44

'

'

250

'

'

30

'

'

205

'

'

37

'

'

'

138

'

'

'

30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1

'

0

'

'

-1

'

0

'

'

120

'

'

7

'

'

113

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring-related Costs Incurred to Date

'

'

144

'

9

'

'

39

'

'

96

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28

'

1

'

'

5

'

22

'

'

76

'

2

'

'

0

'

'

74

'

'

'

'

'

'

'

'

'

'

'

'

40

'

'

6

'

'

34

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated costs of restructuring program by major type of cost

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected total costs associated with the plan

'

'

'

'

'

'

'

'

126

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30

114

22

74

38

175

289

100

137

5

70

225

292

120

140

15

90

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring and Related Cost, Cost Incurred to Date

'

'

468

'

53

'

'

289

'

'

126

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring plan estimated future cash outflow

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

160

280

'

'

'

'

210

283

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments for Restructuring

-29

'

-400

-17

-17

-12

'

-280

0

'

-103

-13

'

-167

'

-6

-6

'

-7

'

-131

'

0

'

-30

'

'

'

'

'

'

'

'

'

'

-2

'

-75

-2

-2

0

'

0

0

'

-73

'

'

'

'

'

'

'

'

'

'

-14

'

-158

'

-9

-9

-5

'

-149

0

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain (Loss) on Sale of Properties

'

19

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring Related Expenses

8

5

144

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

1

1

'

'

'

'

'

'

'

'

2

0

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

5

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

0

0

0

0

0

2

0

0

0

0

0

6

5

0

0

1

1

0

0

0

0

5

4

Restructuring and Related Cost, Incurred Cost

28

15

'

23

'

5

17

'

'

-2

'

11

8

'

'

9

'

'

2

10

'

'

'

-2

'

1

1

'

1

'

0

1

'

0

'

2

0

'

2

'

0

0

'

'

0

'

0

-17

'

0

'

0

-17

'

0

'

14

23

'

'

11

'

3

23

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring Charges

20

10

324

'

'

'

'

'

'

'

'

11

8

'

'

9

'

'

2

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

0

-17

'

'

'

'

'

'

'

'

9

19

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments for Restructuring

-29

'

-400

-17

-17

-12

'

-280

0

'

-103

-13

'

-167

'

-6

-6

'

-7

'

-131

'

0

'

-30

'

'

'

'

'

'

'

'

'

'

-2

'

-75

-2

-2

0

'

0

0

'

-73

'

'

'

'

'

'

'

'

'

'

-14

'

-158

'

-9

-9

-5

'

-149

0

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjustments to the restructuring reserve

'

'

'

'

'

'

'

'

'

'

'

$0

'

'

'

$0

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Supplemental_Balance_Sheet_Inf2

Supplemental Balance Sheet Information (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Allowance for doubtful accounts	'	'	'
Beginning balance	$81	$88	'
Charges to expenses	-2	3	'
Utilization of allowances	-4	-5	'
Ending balance	75	86	'
Trade accounts receivable, net	'	'	'
Accounts receivable	1,322	'	1,419
Less: allowance for doubtful accounts	-75	'	-81
Less: allowance for sales returns	-30	'	-31
Trade accounts receivable, net	1,217	'	1,307
Inventories	'	'	'
Finished goods	611	'	598
Work-in-process	116	'	90
Raw materials	199	'	209
Inventories	926	'	897
Property, plant and equipment, net	'	'	'
Land	81	'	81
Buildings and improvements	919	'	917
Equipment, furniture and fixtures	2,492	'	2,461
Capital in progress	234	'	211
Property, plant and equipment	3,726	'	3,670
Less: accumulated depreciation	2,187	'	2,124
Property, plant and equipment, net	1,539	'	1,546
Accrued expenses	'	'	'
Legal reserves	98	'	84
Payroll and related liabilities	370	'	488
Accrued contingent consideration	228	'	148
Other	579	'	628
Accrued expenses	1,275	'	1,348
Other long-term liabilities	'	'	'
Legal reserves	498	'	523
Accrued income taxes	1,231	'	1,283
Accrued contingent consideration	244	'	353
Other Long-Term Liabilities	425	'	410
Other long-term liabilities	2,398	'	2,569
Accrued warranties	'	'	'
Beginning Balance	28	26	'
Provision	4	4	'
Settlements/ reversals	-3	-3	'
Ending Balance	29	27	'
Supplemental Balance Sheet Information (Textuals) [Abstract]	'	'	'
Depreciation expense	$65	$61	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended			12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Mar. 31, 2015
				Subsequent Event [Member]
Effective Income Tax Rate Reconciliation, Percent [Abstract]	'	'	'	'
Unrecognized Tax Benefits	$1,034	'	$1,069	'
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	922	'	939	'
Reported tax rate	8.90%	10.20%	'	'
Gross interest and penalties recognized in period	14	'	'	'
Net tax expense/benefits related to interest	9	9	'	'
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	416	'	402	'
Potential Reduction In Unrecognized Tax Benefits Over Next Twelve Months As Result Of Concluding Certain Matters	'	'	'	$15

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	7-May-14
				Subsequent Event [Member]
				claims
Commitments and Contingencies (Textuals) [Abstract]	'	'	'	'
Accrual for legal matters that are probable and estimable	$596	'	$607	'
litigation-related charges (credits)	7	-130	'	'
Agreement in principle to settle the defibrillator class action	$3	'	'	'
Product liability cases or claims related to mesh product	'	'	'	20,000

Weighted_Average_Shares_Outsta2

Weighted Average Shares Outstanding (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Weighted average shares outstanding - basic	1,321.70	1,351.90
Weighted Average Number Diluted Shares Outstanding Adjustment	27.5	0
Weighted average shares outstanding - assuming dilution	1,349.20	1,351.90
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	'	12.8
Stock Issued During Period, Shares, New Issues	10	8
Treasury Stock, Shares, Acquired	10	13
Payments for repurchase of common stock, rounded	$125	$100
Stock Options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12	48

Segment_Reporting_Details

Segment Reporting (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
	reportablesegments
Net sales	'	'
Net sales allocated to reportable segments	$1,778	$1,706
Segment Reporting, Sales from Divested Businesses	2	36
Impact of foreign currency fluctuations	-6	19
Net sales	1,774	1,761
Operating Income Allocated to Reportable Segments	405	355
Amortization expense	-109	-103
Operating (loss) income allocated to reportable segments	197	-330
Other expense, net	-51	-64
Income (loss) before income taxes	146	-394
Segment Reporting (Textuals) [Abstract]	'	'
Number of reportable segments	3	'
Global Interventional Cardiology (IC) Reporting Unit [Member]	'	'
Net sales	'	'
Net sales allocated to reportable segments	501	498
Global Peripheral Interventions (PI) Reporting Unit [Member]	'	'
Net sales	'	'
Net sales allocated to reportable segments	204	193
Cardiovascular [Member]	'	'
Net sales	'	'
Net sales allocated to reportable segments	705	691
Operating Income Allocated to Reportable Segments	171	158
Global CRM Reporting Unit [Member]	'	'
Net sales	'	'
Net sales allocated to reportable segments	464	475
Global Electrophysiology (EP) Reporting Unit [Member]	'	'
Net sales	'	'
Net sales allocated to reportable segments	58	34
Rhythm Management [Member]	'	'
Net sales	'	'
Net sales allocated to reportable segments	522	509
Operating Income Allocated to Reportable Segments	66	57
Global Endoscopy (Endo) Reporting Unit [Member]	'	'
Net sales	'	'
Net sales allocated to reportable segments	316	300
Global Urology (Uro) Reporting Unit [Member]	'	'
Net sales	'	'
Net sales allocated to reportable segments	126	117
Global Neuromodulation (NM) Reporting Unit [Member]	'	'
Net sales	'	'
Net sales allocated to reportable segments	109	89
MedSurg [Member]	'	'
Net sales	'	'
Net sales allocated to reportable segments	551	506
Operating Income Allocated to Reportable Segments	168	140
Corporate expenses and currency exchange [Member]	'	'
Net sales	'	'
Operating (Loss) Income Unallocated to Segment	-50	-42
Special Charges [Member]	'	'
Net sales	'	'
Operating (Loss) Income Unallocated to Segment	($49)	($540)

Changes_in_Other_Comprehensive2

Changes in Other Comprehensive Income (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Changes in Other Comprehensive Income [Abstract]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	($22)	($23)	($16)	($26)
Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax	114	109	141	34
Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax	-20	-41	-19	-41
Accumulated Other Comprehensive Income (Loss), Net of Tax	72	45	106	-33
Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease)	-6	3	'	'
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Before Reclassifications, Net of Tax	-14	71	'	'
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, before Reclassification Adjustments, Net of Tax	-1	0	'	'
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	-21	74	'	'
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Reclassified from OCI, Net of Tax	-13	4	'	'
Other Comprehensive Income (Loss), Reclassifications out of OCI, Net of Tax	-13	4	'	'
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	-6	3	'	'
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax	-27	75	'	'
Net change in certain retirement plans	-1	0	'	'
Other Comprehensive Income (Loss), Net of Tax	-34	78	'	'
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax	7	43	'	'
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising Reclassed from OCI, Tax	$8	$2	'	'